Search for a clinical trial
Other search option(s)
373 Result(s)
Recruiting trial
= 
; Ongoing trial
= 
; Funded by an IRDiRC member = 
National clinical trial(s)
AUSTRIA
OBERÖSTERREICH
LINZ
Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel) in Adult Patients With Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML) - AT
Ordensklinikum Linz GmbH Barmherzige Schwestern
Interne I - Internistische Onkologie, Hämatologie u. Gastroenterologie
AUSTRIA
OBERÖSTERREICH
LINZ
Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel) in Adult Patients With Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML) - AT
Ordensklinikum Linz GmbH Elisabethinen
Hämatologie mit Stammzelltransplantation, Hämostaseologie und medizinische Onkologie
AUSTRIA
SALZBURG
SALZBURG
Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel) in Adult Patients With Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML) - AT
Universitätsklinikum der Paracelsus Medizinischen Privatuniversität
Universitätsklinik für Innere Medizin III
AUSTRIA
STEIERMARK
GRAZ
Randomized Phase III Study Comparing Conventional Chemotherapy to Low Dose Total Body Irradiation-Based Conditioning and HCT From Related and Unrelated Donors as Consolidation Therapy for Older Patients With AML in 1st Complete Remission - AT
Medizinische Universität Graz
Klinische Abteilung für Hämatologie
AUSTRIA
TIROL
INNSBRUCK
Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel) in Adult Patients With Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML) - AT
Medizinische Universität Innsbruck
Universitätsklinik für Innere Medizin V - Hämatologie und Onkologie
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
POLO-AML-2: A phase III randomised, double-blind, controlled, parallel group study of intravenous Volasertib in combination with subcutaneous low-dose Cytarabine vs. placebo + low-dose Cytarabine in patients greater or equal to 65 years with previously untreated acute myeloid leukaemia, who are ineligible for intensive remission induction therapy. - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
MIRROS: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase III Study of Idasanutlin, an MDM2 Antagonist, With Cytarabine Versus Cytarabine Plus Placebo in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
A Phase 3, Multicenter, Open-label, Randomized Study of SGI-110 Versus Treatment Choice (TC) in Adults With Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Considered Candidates for Intensive Remission Induction Chemotherapy - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
AMoRe2017: International multicenter, open-label, phase 2 study to treat molecular relapse of pediatric acute myeloid leukemia with Azacitidine - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
WIEN
IDHENTIFY: A Phase 3, Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Hämatologie und Hämostaseologie
AUSTRIA
WIEN
WIEN
VALOR: A Phase 3, Randomized, Controlled, Double-Blind, Multinational Clinical Study of the Efficacy and Safety of Vosaroxin and Cytarabine Versus Placebo and Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Hämatologie und Hämostaseologie
AUSTRIA
WIEN
WIEN
SEAMLESS: A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Hämatologie und Hämostaseologie
AUSTRIA
WIEN
WIEN
Randomized Phase III Study Comparing Conventional Chemotherapy to Low Dose Total Body Irradiation-Based Conditioning and HCT From Related and Unrelated Donors as Consolidation Therapy for Older Patients With AML in 1st Complete Remission - AT
Hanusch Krankenhaus
3. Medizinische Abteilung (Hämatologie und Onkologie)
AUSTRIA
WIEN
WIEN
Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel) in Adult Patients With Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML) - AT
Hanusch Krankenhaus
3. Medizinische Abteilung (Hämatologie und Onkologie)
AUSTRIA
WIEN
WIEN
AML-BFM 2012: Clinical trial for the treatment of acute myeloid leukemia in children and adolescents (phase II-III) - AT
St. Anna Kinderspital
Zentrum für Kinder- und Jugendheilkunde
BELGIUM
ARRONDISSEMENT BRUSSELS-CAPITAL
ADDRESS: NOT PROVIDED - BE
ADMIRAL: A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation- BE
Institution: Information not provided - BE
BELGIUM
ARRONDISSEMENT BRUSSELS-CAPITAL
ADDRESS: NOT PROVIDED - BE
Efficacy Study of Inecalcitol in Combination with Decitabine in Acute Myeloid Leukemia Patients Unfit for Standard Chemotherapy (Phase II) - BE (prematurely ended)
Institution: Information not provided - BE
BELGIUM
ARRONDISSEMENT BRUSSELS-CAPITAL
ADDRESS: NOT PROVIDED - BE
A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia - BE
Institution: Information not provided - BE
BELGIUM
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy - BE
Cliniques Universitaires UCL Saint-Luc
Department of Hematology
BELGIUM
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
AMoRe2017: International multicenter, open-label, phase 2 study to treat molecular relapse of pediatric acute myeloid leukemia with Azacitidine - BE
Hôpital Universitaire des Enfants Reine Fabiola - HUDERF
Service d'hémato-oncologie, d'immunologie et de rhumatologie pédiatrique
BELGIUM
LIEGE
LIEGE
10-day Decitabine, Fludarabine and 2 Gray TBI as Conditioning Strategy for Poor and Very Poor Risk AML in CR1 (phase II)- BE
CHU Sart Tilman - Liège
Department of Hematology / Hématologie clinique
BELGIUM
OOST-VLAANDEREN
GENT
Étude de phase III randomisée et en double-aveugle portant sur l'administration d'une chimiothérapie d'induction (daunorubicine / cytarabine) et de consolidation (cytarabine à haute dose) + midostaurine (PKC412) (IND #101261) ou un placebo chez des patients âgés de moins de 60 ans et nouvellement diagnostiqués comme atteints d'une leucémie myéloïde aiguë (LMA) avec mutation du gène FLT3 - BE
Ghent University Hospital - UZ Gent
Dienst Hematologie
BELGIUM
VLAAMS BRABANT
LEUVEN
A single arm Phase I/II study of the safety and efficacy of gene-modified WT1 TCR therapy in patients with myelodysplastic syndrome (MDS) or acute myeloid leukaemia (AML) who have failed to achieve or maintain an IWG defined response following hypomethylating agent therapy - BE
University Hospitals Leuven - Gasthuisberg
Department of Hematology
FINLAND
Finland
HELSINKI
Clinical Phase III Trial to Compare Treosulfan-based Conditioning Therapy With Busulfan-based Reduced-intensity Conditioning (RIC) Prior to Allogeneic Haematopoietic Stem Cell Transplantation in Patients With AML or MDS Considered Ineligible to Standard Conditioning Regimens - FI
HUCH - Helsinki University Central Hospital
Deparment of Medicine
FRANCE
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
Clinical Phase III Trial to Compare Treosulfan-based Conditioning Therapy With Busulfan-based Reduced-intensity Conditioning (RIC) Prior to Allogeneic Haematopoietic Stem Cell Transplantation in Patients With AML or MDS Considered Ineligible to Standard Conditioning Regimens - FR
Institution: Information not provided - FR
FRANCE
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
A phase Ib, open-label, multi-center dose-finding study of oral panobinostat (LBH589) in combination with Ara-C and mitoxantrone as salvage therapy for refractory or relapsed acute myeloid leukemia - FR
Institution: Information not provided - FR
FRANCE
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
A phase 2 open-label, AC220 monotherapy efficacy (ACE) study in patients with acute myeloid leukemia (AML) with FLT3-ITD activating mutations - FR
Institution: Information not provided - FR
FRANCE
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
A randomised phase III study of elacytarabine vs. investigator's choice in patients with late stage acute myeloid leukemia - FR
Institution: Information not provided - FR
FRANCE
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
Study PMA112509, a phase I/II study of Eltrombopag in thrombocytopenic subjects with advanced MyeloDysplastic Syndrome (MDS) or secondary Acute Myeloid Leukemia after MDS (sAML/MDS) - FR
Institution: Information not provided - FR
FRANCE
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
An open phase I/IIa trial to investigate the maximum tolerated dose, safety, pharmacokinetics and efficacy of intraveneous BI 6727 as monotherapy or in combination with subcutaneous cytarabine in patients with acute myeloid leukaemia - FR
Institution: Information not provided - FR
FRANCE
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
A Phase I/II study of clofarabine in combination with cytarabine and liposomal daunorubicin in children with relapsed/refractory pediatric AML - FR
Institution: Information not provided - FR
FRANCE
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PKC412) (IND #101261) or Placebo in Newly Diagnosed Patients < 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia (AML) - FR
Institution: Information not provided - FR
FRANCE
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
A Phase 1/2 Open-Label, Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia - FR (Prematurely Ended)
Institution: Information not provided - FR
FRANCE
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
Phase I dose-escalation study of the orally administrered selective Bcl-2 inhibitor S055746 as monotherapy for the treatment of patients with Acute Myeloid Leukaemia (AML) or high or very high risk Myelodysplastic Syndrome (MDS) - FR
Institution: Information not provided - FR
FRANCE
AUVERGNE-RHONE-ALPES
LYON
A Phase Ib/II Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission - FR
CLCC Léon Bérard
Centre Léon Bérard
FRANCE
ILE-DE-FRANCE
PARIS
A Phase Ib/II Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission - FR
CHU Paris-GH St-Louis Lariboisière F.Widal - Hôpital Saint-Louis
Hôpital Saint Louis
FRANCE
ILE-DE-FRANCE
PARIS
A Phase 3 Open-label Randomized Study of Quizartinib AC220 Monotherapy Versus Salvage Chemotherapy in Subjects With Feline McDonough Sarcoma FMS Like Tyrosine Kinase 3 Internal Tandem Duplication FLT3 ITD Positive Acute Myeloid Leukemia AML Refractory to or Relapsed After First-line Treatment With or Without Hematopoietic Stem Cell Transplantation HSCT Consolidation - FR
CHU Paris-GH St-Louis Lariboisière F.Widal - Hôpital Saint-Louis
Service : Centre des Maladies du Sang
FRANCE
ILE-DE-FRANCE
PARIS
SAMBA-trial: Investigation of efficacy of the antibody JNJ-56022473 in MDS and AML patients, in which the treamtment with hypomethylating agents fails or the treatment with hypomethylating agents results in a relapse (Phase II) - FR
CHU Paris-GH St-Louis Lariboisière F.Widal - Hôpital Saint-Louis
Service d'Hématologie seniors
FRANCE
OCCITANIE
TOULOUSE
A Phase Ib/II Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission - FR
IUCT Oncopole - CLCC Institut Claudius Regaud
Bureau des études cliniques
FRANCE
PAYS DE LA LOIRE
NANTES
FRANCE
PAYS DE LA LOIRE
NANTES
SET-RIC: Clofarabine/Ara-C Treatment Combined With Reduced-intensity Conditioning Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Primary Treatment Failure - FR
CHU de Nantes - Hôtel Dieu
Service d'hématologie clinique
FRANCE
PAYS DE LA LOIRE
NANTES
Etude randomisée de phase III comparant une chimiothérapie conventionnelle de consolidation à une allogreffe de cellules souches hématopoïétiques conditionnée par fludarabine et irradiation corporelle totale à faible dose, chez des patients âgés atteints de leucémie aiguë myéloïde en première rémission complète - FR
CHU de Nantes - Hôtel Dieu
Service d'hématologie clinique
FRANCE
PROVENCE-ALPES-COTE D'AZUR
MARSEILLE
EFFIKIR : Double-Blind Placebo-Controlled Randomized Phase 2 Study of IPH2102 as Maintenance Treatment in Elderly patients with Acute Myeloid Leukemia (AML) in First Complete Remission
CLCC Institut Paoli Calmettes
Unité d'Evaluation Thérapeutique en Onco-Hématologie (ETHO)
FRANCE
PROVENCE-ALPES-COTE D'AZUR
MARSEILLE
A Phase Ib/II Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission - FR
CLCC Institut Paoli Calmettes
Institut Paoli-Calmettes
GERMANY
Baden-Württemberg
FREIBURG
AMLSG 14-09 (DECIDER): Prospective randomized multicenter phase II trial of low-dose Decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor Valproic Acid (VPA) and All-trans Retinoic Acid (ATRA) in patients > 60 years with Acute Myeloid Leukemia who are ineligible for induction chemotherapy
Universitätsklinikum Freiburg
Klinik für Innere Medizin I - Hämatologie, Onkologie und Stammzelltransplantation
GERMANY
Baden-Württemberg
FREIBURG
TRANSATRA: Phase I/II Study of Sensitization of Non-M3 Acute Myeloid Leukemia (AML) Blasts to All-trans Retinoic Acid (ATRA) by Epigenetic Treatment with Tranylcypromine (TCP), an Inhibitor of the Histone Lysine Demethylase 1 (LSD1) - DE
Universitätsklinikum Freiburg
Klinik für Innere Medizin I - Hämatologie, Onkologie und Stammzelltransplantation
GERMANY
Baden-Württemberg
FREIBURG
CA209-9P9: Phase 1/2 Study on the Efficacy of Nivolumab in the Recurrence of Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation
Universitätsklinikum Freiburg
Klinik für Innere Medizin I - Hämatologie, Onkologie und Stammzelltransplantation
GERMANY
Baden-Württemberg
HEIDELBERG
BLAST: A double- blind, placebo controlled, randomized, multicenter, Phase II study to assess the efficacy of BL-8040 addition to consolidation therapy in AML patients - DE
Zentrum für Innere Medizin (Krehl-Klinik)
Abteilung Innere Medizin V - Hämatologie, Onkologie und Rheumatologie
GERMANY
Baden-Württemberg
ULM
GERMANY
Baden-Württemberg
ULM
Phase 1b Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia -DE-
Universitätsklinikum Ulm
GERMANY
Baden-Württemberg
ULM
An open phase I/IIa trial to investigate the maximum tolerated dose, safety, pharmacokinetics, and efficacy of intravenous BI 6727 as monotherapy or in combination with subcutaneous Cytarabine in patients with Acute Myeloid Leukemia (AML) - DE
Universitätsklinikum Ulm am Oberen Eselsberg
Klinik für Innere Medizin III
GERMANY
Baden-Württemberg
ULM
AMLSG 21-13: Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib in Adult Patients With Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML) - DE
Universitätsklinikum Ulm am Oberen Eselsberg
Klinik für Innere Medizin III
GERMANY
Baden-Württemberg
ULM
SOPRA: A Randomized, Open Label, Phase 2 Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) versus Specified Physician's Choice in Patients 60 Years and older with Relapsed/Refractory Acute Myeloid Leukemia (AML) Who are Ineligible for Intensive Chemotherapy and/or Transplantation - DE
Universitätsklinikum Ulm am Oberen Eselsberg
Klinik für Innere Medizin III
GERMANY
Baden-Württemberg
ULM
A Phase 3, Multicenter, Open-label, Randomized Study of SGI-110 versus Treatment Choice (TC) in Adults with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Considered Candidates for Intensive Remission Induction Chemotherapy - DE
Universitätsklinikum Ulm am Oberen Eselsberg
Klinik für Innere Medizin III
GERMANY
Baden-Württemberg
ULM
The IDHENTIFY Trial: A Phase 3, Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects with Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation - DE
Universitätsklinikum Ulm am Oberen Eselsberg
Klinik für Innere Medizin III
GERMANY
Baden-Württemberg
ULM
A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia -DE-
Universitätsklinikum Ulm am Oberen Eselsberg
Klinik für Innere Medizin III
GERMANY
Bayern
REGENSBURG
AMLSG 26-16 / AML-ViVA: Randomized Phase II trial with safety run-in phase evaluating low-dose azacitidine, all-trans retinoic acid and pioglitazone versus standard dose azacitidine in patients >=60 years with acute myeloid leukemia (AML) who are refractory to standard induction chemotherapy - DE
Universitätsklinikum Regensburg
Klinik und Poliklinik für Innere Medizin III
GERMANY
Berlin
ADDRESS: NOT PROVIDED - DE
A Phase 1/2 Open-Label, Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia - DE
Institution: Information not provided - DE
GERMANY
Berlin
ADDRESS: NOT PROVIDED - DE
A phase IB/II study to evaluate the safety and efficacy of vismodegib in relapsed/refractory acute myelogenous leukemia (AML) and relapsed/refractory high-risk myelodysplastic syndrome (MDS) - DE-
Institution: Information not provided - DE
GERMANY
Berlin
ADDRESS: NOT PROVIDED - DE
SAIL: An Investigator-Initiated Study To Evaluate Ara-C and Idarubicin in Combination with the Selective Inhibitor Of Nuclear Export (SINE) Selinexor (KPT-330) in Patients with Relapsed Or Refractory AML
Institution: Information not provided - DE
GERMANY
Berlin
ADDRESS: NOT PROVIDED - DE
International multicenter, open-label, phase 2 study to treat molecular relapse of pediatric acute myeloid leukemia with azacitidine -GB
Institution: Information not provided - DE
GERMANY
Berlin
ADDRESS: NOT PROVIDED - DE
A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy -DE-
Institution: Information not provided - DE
GERMANY
Berlin
BERLIN
AMoRe2017: International multicenter, open-label, phase 2 study to treat molecular relapse of pediatric acute myeloid leukemia with Azacitidine -DE-
Otto-Heubner-Centrum für Kinder- und Jugendmedizin
Klinik für Pädiatrie mit Schwerpunkt Onkologie und Hämatologie
GERMANY
Hamburg
HAMBURG
Phase 1b Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia -DE-
UKE - Universitätsklinikum Hamburg-Eppendorf
GERMANY
Hessen
FRANKFURT AM MAIN
TOR-AML: A double-blind, placebo-controlled, randomized, multicenter phase II trial to assess the efficacy of Temsirolimus added to standard primary therapy in elderly patients with newly diagnosed Acute Myeloid Leukemia (AML)
Universitäres Centrum für Tumorerkrankungen (UCT) Frankfurt
Comprehensive Cancer Center (CCC) Frankfurt
GERMANY
Hessen
FRANKFURT AM MAIN
A Randomized Phase 2/3 Study of DACOGEN® (Decitabine) plus JNJ-56022473 (Anti-CD123) Versus DACOGEN (Decitabine) Alone in Patients with AML who are not Candidates for Intensive Chemotherapy - DE
Universitäres Centrum für Tumorerkrankungen (UCT) Frankfurt
Comprehensive Cancer Center (CCC) Frankfurt
GERMANY
Niedersachsen
BRAUNSCHWEIG
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase III Study of Idasanutlin, an MDM2 Antagonist, With Cytarabine Versus Cytarabine Plus Placebo in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) - DE
Städtisches Klinikum Braunschweig - Standort Celler Straße
Medizinische Klinik III - Hämatologie und Onkologie
GERMANY
Niedersachsen
HANNOVER
ClAraC-SCT: Randomized, multicentre, phase II trial to compare the event-free survival of Clofarabine / Ara-C (ClAraC) or of FLAMSA treatment in patients with high risk AML or advanced MDS scheduled for allogeneic stem cell transplantation
Medizinische Hochschule Hannover
Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation
GERMANY
Nordrhein-Westfalen
BONN
An International, Multicentre, Open-label Study To Evaluate The Efficacy and Safety of Two Different Vaccination Regimens of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia That Are In Remission With Persistent MRD -DE-
Universitätsklinikum Bonn (AöR)
Universitätsklinikum Bonn
GERMANY
Nordrhein-Westfalen
DÜSSELDORF
MDS/AML Eltrombopag: a phase I/II study of Eltrombopag in thrombocytopenic subjects with advanced MyeloDysplastic Syndrome (MDS) or secondary Acute Myeloid Leukemia after MDS - DE
Universitätsklinikum Düsseldorf
Klinik für Hämatologie, Onkologie und Klinische Immunologie
GERMANY
Nordrhein-Westfalen
ESSEN
AML-BFM 2012: Clinical trial for the treatment of acute myeloid leukemia in children and adolescents
Universitätsklinikum Essen
Klinik für Kinderheilkunde III - Abteilung für pädiatrische Hämatologie und Onkologie
GERMANY
Nordrhein-Westfalen
ESSEN
Clinical Phase III Trial to compare Treosulfan-based conditioning therapy with Busulfan-based reduced-intensity conditioning (RIC) prior to allogeneic haematopoietic Stem Cell Transplantation in patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) considered ineligible to standard conditioning regimens - DE
Universitätsklinikum Essen
Klinik für Knochenmarktransplantation
GERMANY
Nordrhein-Westfalen
LEVERKUSEN
CLAVELA: A randomised phase III study of Elacytarabine versus investigator's choice in patients with late stage Acute Myeloid Leukaemia - DE - Completed
Klinikum Leverkusen
Medizinische Klinik 3 - Onkologie, Hämatologie, Palliativmedizin, Spezielle Schmerztherapie
GERMANY
Nordrhein-Westfalen
MÜNSTER
PAZOPANIB-AML: Phase II Pilot Clinical Trial of Pazopanib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible - DE
Universitätsklinikum Münster
Medizinische Klinik und Poliklinik A
GERMANY
Rheinland-Pfalz
MAINZ
GERMANY
Sachsen
DRESDEN
CALGB 10603: A Phase III randomized, double-blind study of induction (Daunorubicin/Cytarabine) and consolidation (High-Dose Cytarabine) chemotherapy + Midostaurin (PKC412) or Placebo in newly diagnosed patients < 60 years of age with FLT3 mutated Acute Myeloid Leukemia (AML)
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I
GERMANY
Sachsen
DRESDEN
MIDOKIT (TUD-MIDOKI-052): A single-arm phase II trial to assess the efficacy of Midostaurin (PKC412) added to standard primary therapy in patients with newly diagnosed c-KIT or FLT3-ITD mutated t(8;21) AML
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I
GERMANY
Sachsen
DRESDEN
DaunoDouble: Randomized comparison between two dose levels of Daunorubicin and between one versus two cycles of induction therapy for adult patients with Acute Myeloid Leukemia
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I
GERMANY
Sachsen
DRESDEN
A Multicenter, Open-label, Dose-escalating, Phase I Trial With GEM333, a CD33 Targeted Bispecific Antibody Engaging T-cells, in Relapsed or Refractory Acute Myeloid Leukemia - DE
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I
GERMANY
Sachsen
DRESDEN
TUD-BRIDGE-046: Clofarabine salvage therapy in patients with relapsed or refractory Acute Myeloid Leukemia (Phase II Study)
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I - Fachbereich Hämatologie und Blutstammzelltransplantation
GERMANY
Sachsen
DRESDEN
HINKL: Randomised controlled phase-2 trial to determine the efficacy of adoptive immunotherapy with haploidentical natural killer cells in high-risk acute myeloid leukemia - DE
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I - Fachbereich Hämatologie und Blutstammzelltransplantation
GERMANY
Sachsen
DRESDEN
DELTA: A randomized placebo-controlled phase 2 study of decitabine/azacitidine with or without eltrombopag in AML patients = / > 65 years of age not eligible for intensive chemotherapy - DE
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I - Fachbereich Hämatologie und Blutstammzelltransplantation
GERMANY
Sachsen
DRESDEN
ETAL3-ASAP: Evaluation of the Impact of Remission Induction Chemotherapy Prior to Allogeneic Stem Cell Transplantation in Relapsed and Poor-response Patients with AML (Phase III) - DE
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I - Fachbereich Hämatologie und Blutstammzelltransplantation
GERMANY
Sachsen
DRESDEN
SAMBA: Single Agent JNJ-56022473 in MDS and AML Patients Failing Hypomethylating Agent Based Therapy -DE-
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I - Fachbereich Hämatologie und Blutstammzelltransplantation
GERMANY
Sachsen
DRESDEN
A single arm Phase I/II study of the safety and efficacy of gene-modified WT1 TCR therapy in patients with myelodysplastic syndrome (MDS) or acute myeloid leukaemia (AML) who have failed to achieve or maintain an IWG defined response following hypomethylating agent therapy -Prematurely Ended -DE-
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Universitätsklinikum Dresden
GERMANY
Sachsen
DRESDEN
Phase 1b Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia -DE-
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Universitätsklinikum Dresden
GERMANY
Sachsen
LEIPZIG
HCT vs CT in elderly AML: Randomized Phase III study comparing conventional chemotherapy to low dose total body irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors as consolidation therapy for older Patients with Acute Myeloid Leukemia in first Complete Remission - DE
Abteilung für Hämatologie und Internistische Onkologie
GERMANY
Sachsen
LEIPZIG
AML 2004 OSHO#069: Randomized phase III study comparing the OSHO arm to the standard intergroup arm - Efficacy of allogeneic stem cell transplantation in comparison to a second consolidation chemotherapy in elderly patients with newly diagnosed Acute Myeloid Leukemia (AML) in the age over 60 years
Abteilung für Hämatologie und Internistische Onkologie
GERMANY
Sachsen
LEIPZIG
An International, Multicentre, Open-label Study To Evaluate The Efficacy and Safety of Two Different Vaccination Regimens of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia That Are In Remission With Persistent MRD -DE-
Universitätsklinikum Leipzig AöR
UCCL - Universitäres Krebszentrum Leipzig
ITALY
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
A Phase Ib/II Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission - IT
Institution: Information not provided - IT
ITALY
EMILIA ROMAGNA
BOLOGNA
A phase 2 open-label, AC220 monotherapy efficacy (ACE) study in patients with acute myeloid leukemia (AML) with FLT3-ITD activating mutations - IT
Policlinico S. Orsola-Malpighi - Area S. Orsola
Università di Bologna
NETHERLANDS
Zuid-Holland
LEIDEN
POLAND
Wroclaw
WROCLAW
CLAVELA: A Randomised Phase III Study of Elacytarabine vs. Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia - PL
Uniwersytet Medyczny im. Piastow Slaskich - Wroclaw Medical University
Klinika Hematologii, Nowotworow Krwi i Transplantacji Szpiku
SPAIN
Andalucía
MÁLAGA
A Phase 1b/2 Open-Label, Randomized Study of 2 Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine: Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus SC Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia Harboring an IDH1 or an IDH2 Mutation, Respectively [...] - ES
Hospital Regional Universitario de Málaga - Hospital General
Unidad de Gestión Clínica de Hematología
SPAIN
Baleares
PALMA DE MALLORCA
SPAIN
Baleares
PALMA DE MALLORCA
CLAVELA: A Randomised Phase III Study of Elacytarabine vs. Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia - ES (completed)
Hospital Universitario Son Espases
Unidad de Coagulopatías Congénitas
SPAIN
Castilla - León
SALAMANCA
Phase 2 Open-Label, AC220 Monotherapy Efficacy (ACE) Study in Patients With Acute Myeloid Leukemia (AML) With FLT3-ITD Activating Mutations - ES (Completed)
Hospital Clínico Universitario de Salamanca
Servicio de Hematología
SPAIN
Cataluña
BADALONA
Phase 2 Open-Label, AC220 Monotherapy Efficacy (ACE) Study in Patients With Acute Myeloid Leukemia (AML) With FLT3-ITD Activating Mutations - ES (Completed)
ICO Badalona - Hospital Germans Trias i Pujol
Servicio de Hematología Clínica
SPAIN
Cataluña
BADALONA
SOPRA: A Randomized, Open Label, Phase 2 Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) versus Specified Physician s Choice in Patients older or equal to 60 Years Old with Relapsed/Refractory Acute Myeloid Leukemia (AML) [...] - ES (Completed)
ICO Badalona - Hospital Germans Trias i Pujol
Servicio de Hematología Clínica
SPAIN
Cataluña
BADALONA
A Phase 3 Open-Label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory To or Relapsed After First-line Treatment With or Without Hematopoietic Stem Cell Transplant (HSCT) Consolidation - ES
ICO Badalona - Hospital Germans Trias i Pujol
Servicio de Hematología Clínica
SPAIN
Cataluña
BARCELONA
Phase 2 Open-Label, AC220 Monotherapy Efficacy (ACE) Study in Patients With Acute Myeloid Leukemia (AML) With FLT3-ITD Activating Mutations - ES (Completed)
Hospital Clínic de Barcelona
Servicio de Hematología
SPAIN
Cataluña
BARCELONA
A Phase 1b/2 Open-Label, Randomized Study of 2 Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine: Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus SC Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia Harboring an IDH1 or an IDH2 Mutation, Respectively [...] - ES
Hospital Clínic de Barcelona
Servicio de Hematología
SPAIN
Cataluña
BARCELONA
SPAIN
Cataluña
BARCELONA
Phase 2 Open-Label, AC220 Monotherapy Efficacy (ACE) Study in Patients With Acute Myeloid Leukemia (AML) With FLT3-ITD Activating Mutations - ES (Completed)
Hospital de la Santa Creu i Sant Pau
Servicio de Hematología
SPAIN
Cataluña
BARCELONA
Treatment of de Novo Acute Myeloid Leukemia With the Combination of Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin (Mylotarg ®), Associated or Not Priming With G-CSF. Prospective Study of Efficacy and Toxicity (Phase II) - ES
Hospital de la Santa Creu i Sant Pau
Servicio de Hematología
SPAIN
Cataluña
BARCELONA
Treatment of di Novo Acute Myeloid Leukemia With the Combination of Increasing Doses of Idarubicin, Cytarabine and Sensitization (Priming) With G-CSF. A Phase II Prospective Study of Toxicity and Efficacy (completed)
Hospital de la Santa Creu i Sant Pau
Servicio de Hematología
SPAIN
Cataluña
BARCELONA
POLO-AML-2: A Phase III Randomised, Double-blind, Controlled, Parallel Group Study of Intravenous Volasertib in Combination With Subcutaneous Low-dose Cytarabine vs. Placebo + Low-dose Cytarabine in Patients >=65 Years With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy - ES (Completed)
Hospital de la Santa Creu i Sant Pau
Servicio de Hematología
SPAIN
Cataluña
GIRONA
Phase 2 Open-Label, AC220 Monotherapy Efficacy (ACE) Study in Patients With Acute Myeloid Leukemia (AML) With FLT3-ITD Activating Mutations - ES (Completed)
ICO Girona - Hospital Universitario Doctor Josep Trueta
Servicio de Hematología Clínica
SPAIN
Cataluña
L'HOSPITALET DE LLOBREGAT
A Phase 1b/2 Open-Label, Randomized Study of 2 Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine: Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus SC Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia Harboring an IDH1 or an IDH2 Mutation, Respectively [...] - ES
ICO Hospitalet - Hospital Duran i Reynals
Servicio de Hematología Clínica
SPAIN
Comunidad Valenciana
VALENCIA
Phase 2 Open-Label, AC220 Monotherapy Efficacy (ACE) Study in Patients With Acute Myeloid Leukemia (AML) With FLT3-ITD Activating Mutations - ES (Completed)
Hospital Universitario y Politécnico La Fe
Servicio de Hematología y Hemoterapia
SPAIN
Comunidad Valenciana
VALENCIA
PETHEMA-LMA10: Protocol for first line treatment adapted to risk of acute myeloblastic leukemia in patients less than or equal to 65 years
Hospital Universitario y Politécnico La Fe
Servicio de Hematología y Hemoterapia
SPAIN
Comunidad Valenciana
VALENCIA
Multicenter, Prospective, Open-label, Single-arm, Phase I-II Clinical Trial to Analyze Induction Therapy With a Combination of Fludarabine, Idarubicin, Cytarabine, G-CSF and Plerixafor for the Treatment of Young Patients With Relapsed or Refractory acute myeloid leukemia - ES (Completed)
Hospital Universitario y Politécnico La Fe
Servicio de Hematología y Hemoterapia
SPAIN
Comunidad Valenciana
VALENCIA
A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia - ES (Completed)
Hospital Universitario y Politécnico La Fe
Servicio de Hematología y Hemoterapia
SPAIN
Comunidad Valenciana
VALENCIA
IDHENTIFY: A Phase 3, Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects with Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation - ES
Hospital Universitario y Politécnico La Fe
Servicio de Hematología y Hemoterapia
SPAIN
Comunidad Valenciana
VALENCIA
A Randomized Phase 2 Study of DACOGEN® (Decitabine) Plus JNJ-56022473 (Anti-CD123) Versus DACOGEN (Decitabine) Alone in Patients with AML who are not Candidates for Intensive Chemotherapy - ES (completed)
Hospital Universitario y Politécnico La Fe
Servicio de Hematología y Hemoterapia
SPAIN
Comunidad Valenciana
VALENCIA
A Phase 1b/2 Open-Label, Randomized Study of 2 Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine: Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus SC Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia Harboring an IDH1 or an IDH2 Mutation, Respectively [...] - ES
Hospital Universitario y Politécnico La Fe
Servicio de Hematología y Hemoterapia
SPAIN
Extremadura
CÁCERES
A Phase 1b/2 Open-Label, Randomized Study of 2 Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine: Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus SC Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia Harboring an IDH1 or an IDH2 Mutation, Respectively [...] - ES
Hospital San Pedro de Alcántara
Servicio de Hematología y Hemoterapia
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 3, Multicenter, Open-label, Randomized Study of SGI-110 versus Treatment Choice (TC) in Adults with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Considered Candidates for Intensive Remission Induction Chemotherapy - ES (completed)
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy - ES
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
Efficacy Study of Inecalcitol in Combination with Decitabine in Acute Myeloid Leukemia Patients Unfit for Standard Chemotherapy (Phase II) - ES (completed)
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia - ES
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy -GB
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 2, Randomized, Biomarker-driven, Clinical Study in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with an Exploratory Arm in Patients with Newly Diagnosed High-Risk AML (Completed) - ES
Institution: Information not provided - ES
SPAIN
Madrid
MADRID
A Phase 1b/2 Open-Label, Randomized Study of 2 Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine: Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus SC Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia Harboring an IDH1 or an IDH2 Mutation, Respectively [...] - ES
Hospital General Universitario Gregorio Marañón
Servicio de Hematología y Hemoterapia
SPAIN
Madrid
MADRID
A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PKC412) (IND #101261) or Placebo in Newly Diagnosed Patients < 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia (AML) - ES (terminated)
Hospital Universitario 12 de Octubre
Servicio de Hematología y Hemoterapia
SPAIN
Madrid
MADRID
A Phase 1b/2 Open-Label, Randomized Study of 2 Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine: Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus SC Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia Harboring an IDH1 or an IDH2 Mutation, Respectively [...] - ES
M.D. Anderson Cancer Center Madrid
M.D. Anderson International España
SPAIN
Navarra
PAMPLONA
Phase 2 Open-Label, AC220 Monotherapy Efficacy (ACE) Study in Patients With Acute Myeloid Leukemia (AML) With FLT3-ITD Activating Mutations - ES (Completed)
Clínica Universidad de Navarra
Área de Terapia Celular
SPAIN
Navarra
PAMPLONA
CLAVELA: A Randomised Phase III Study of Elacytarabine vs. Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia - ES (completed)
Complejo Hospitalario de Navarra - Hospital Virgen del Camino
Servicio de Hematología y Hemoterapia
SWITZERLAND
Suisse Alémanique
BASEL
A phase IB/II study to evaluate the safety and efficacy of vismodegib in relapsed/refractory acute myelogenous leukemia (AML) and relapsed/refractory high-risk myelodysplastic syndrome (MDS) - DE-
Hoffmann-La Roche
Hoffmann - La Roche Ltd.
SWITZERLAND
Suisse Romande
ADDRESS: NOT PROVIDED - CH
AMoRe2017: International multicenter, open-label, phase 2 study to treat molecular relapse of pediatric acute myeloid leukemia with Azacitidine - CH
Institution: Information not provided - CH
SWITZERLAND
Suisse Romande
ADDRESS: NOT PROVIDED - CH
A Phase 1b/2 Open-Label, Randomized Study of 2 Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine: Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus SC Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia Harboring an IDH1 or an IDH2 Mutation, Respectively [...] - CH
Institution: Information not provided - CH
UNITED KINGDOM
Avon
BRISTOL
A Phase 3 Open-Label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory To or Relapsed After First-line Treatment With or Without Hematopoietic Stem Cell Transplant (HSCT) Consolidation - UK
Bristol Royal Hospital for Children
Bristol Haematology and Oncology Centre
UNITED KINGDOM
Avon
BRISTOL
A Phase 2, Randomized, Biomarker-driven, Clinical Study in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with an Exploratory Arm in Patients with Newly Diagnosed High-Risk AML -GB
Bristol Royal Infirmary
University Hospitals Bristol NHS Foundation Trust HQ
UNITED KINGDOM
Glasgow
GLASGOW
MyeChild 01: International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia - Incorporating an Embedded Dose Finding Study for Gemtuzumab Ozogamicin in Combination With Induction Chemotherapy - UK
Royal Hospital For Children, NHS Greater Glasgow & Clyde
Paediatrics (Ground Floor, Zone 1)
UNITED KINGDOM
Greater London
LONDON
A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia - UK
King's College Hospital
King's College Hospital NHS Foundation Trust HQ
UNITED KINGDOM
Greater Manchester
ADDRESS: NOT PROVIDED - UK
Phase 2 Open-Label, AC220 Monotherapy Efficacy (ACE) Study in Patients With Acute Myeloid Leukemia (AML) With FLT3-ITD Activating Mutations - UK
Institution: Information not provided - UK
UNITED KINGDOM
Greater Manchester
ADDRESS: NOT PROVIDED - UK
CLAVELA: A Randomised Phase III Study of Elacytarabine vs. Investigators Choice in Patients with Late Stage Acute Myeloid Leukaemia - UK
Institution: Information not provided - UK
UNITED KINGDOM
Greater Manchester
ADDRESS: NOT PROVIDED - UK
CALGB 10603: A phase III randomized, double-blind study of induction (daunorubicin/cytarabine) and consolidation (high dose cytarabine) chemotherapy + midostaurin (PKC412) or placebo in newly diagnosed patients < 60 years of age with FLT3 mutated acute myeloid leukemia (AML) - UK
Institution: Information not provided - UK
UNITED KINGDOM
Greater Manchester
ADDRESS: NOT PROVIDED - UK
A Phase 1/2, Open-Label, Multi-Center Dose Escalation, Safety and Tolerability Study of AKN-028 in Patients with Acute Myelogenous Leukemia (AML) - GB
Institution: Information not provided - UK
UNITED KINGDOM
Nottinghamshire
NOTTINGHAM
AML18: A Trial for Older Patients with Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome (Phase III) - UK
LAM Action Nottingham, Voluntary Action Centre
Department of Haematology
UNITED KINGDOM
Oxfordshire
OXFORD
A Phase 1b Trial of Hu5F9-G4 Monotherapy or Hu5F9-G4 in Combination With Azacitidine in Patients With Hematological Malignancies
Churchill Hospital
Department of Haematology
UNITED KINGDOM
South Glamorgan
CARDIFF
AML 14: A Randomised Trial for Patients with Acute Myeloid Leukaemia or High Risk Myelodysplastic Syndrome Aged 60 or over (phase III)
Cardiff University School of Medicine
Department of Medical Genetics, Haematology & Pathology
UNITED KINGDOM
South Glamorgan
CARDIFF
Phase 1b Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia-GB
University Hospital of Wales
Department of Haematology
UNITED STATES
Washington
ADDRESS: NOT PROVIDED - US
A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PKC412) (IND #101261) or Placebo in Newly Diagnosed Patients < 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia (AML) - US
Institution: Information not provided - US
UNITED STATES
Washington
ADDRESS: NOT PROVIDED - US
A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia -GB
Institution: Information not provided - US
GERMANY
Sachsen
DRESDEN
RELAZA2 (TUD-RELA02-048): Treatment of patients with Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) with an impending hematological relapse with Azacitidin (Phase II)
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I - Fachbereich Hämatologie und Blutstammzelltransplantation
AUSTRIA
WIEN
WIEN
AML SCT-BFM 2007 : Phase III multicenter therapy study: Allogenic Stem Cell Transplantation for children, adolescents and young adults with relapsed or refractory Acute myeloid Leukemia (AML) - AT
St. Anna Kinderspital
Zentrum für Kinder- und Jugendheilkunde
AUSTRIA
WIEN
WIEN
Clinical Phase II Trial to Describe the Safety and Efficacy of Treosulfan-based Conditioning Therapy Prior to Allogeneic Haematopoietic Stem Cell Transplantation in Paediatric Patients With Haematological Malignancies - AT
St. Anna Kinderspital
Zentrum für Kinder- und Jugendheilkunde
BELGIUM
ANTWERPEN
ANTWERPEN
A Randomized, Double Blind Phase 1b/2 Study Of Pf 04449913 (Glasdegib) In Combination With Azacitidine In Patients With Previously Untreated Intermediate 2 Or High Risk Myelodysplastic Syndrome, Acute Myeloid Leukemia With 20-30% Blasts And Multi Lineage Dysplasia, Or Chronic Myelomonocytic Leukemia - BE
Ziekenhuis Netwerk Antwerpen (ZNA) - Campus Stuivenberg
Hematologie (Bloedziekten)
BELGIUM
ANTWERPEN
ANTWERPEN
HOVON 116 AML: A phase I/II feasibility study of panoninostat alone and the combination of panobinostat and decitabine prior to donor lymphocyte infusion in recipients of allogeneic stem cell transplantation with poor and very poor risk AML- BE
Ziekenhuis Netwerk Antwerpen (ZNA) - Campus Stuivenberg
Hematologie (Bloedziekten)
BELGIUM
ANTWERPEN
ANTWERPEN-EDEGEM
Therapeutic efficacy of Wilms tumor gene (WT1) mRNA-electroporated autologous dendritic cell vaccination in patients with myeloid malignancies and multiple myeloma: a phase II trial
University Hospital of Antwerp - UZA
Department of Hematology
BELGIUM
ARRONDISSEMENT BRUSSELS-CAPITAL
ADDRESS: NOT PROVIDED - BE
A Randomized, Blinded, Placebo-Controlled, Dose Finding Study to Assess the Safety and Efficacy of the Oral Thrombopoietin Receptor Agonist, Eltrombopag, Administered to Subjects with Acute Myelogenous Leukaemia (AML) Receiving Induction Chemotherapy (phase II)- BE (completed)
Institution: Information not provided - BE
BELGIUM
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Sequential administration of 5-azacytidine (AZA) and donor lymphocyte infusion (DLI) for patients with acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) in relapse after allogeneic stem cell transplantation.
Cliniques Universitaires UCL Saint-Luc
Cliniques Universitaires Saint-Luc
BELGIUM
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
CR-AIR-008: An Exploratory, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of a Two-dose Regimen of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted ex Vivo of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy, Who Received a CD34-selected Hematopoietic Stem Cell Transplantation From a Haploidentical Donor (phase II)- BE (terminated)
Institut Jules Bordet
Service d'hématologie
BELGIUM
BRABANT WALLON
MONT-SAINT-GUIBERT
BELGIUM
LIEGE
LIEGE
Co-transplantation of Mesenchymal Stem Cells and HLA-mismatched Allogeneic Hematopoietic Cells After Nonmyeloablative Conditioning: a Phase II Randomized Double-blind Study
CHU Sart Tilman - Liège
Department of Hematology / Hématologie clinique
BELGIUM
NAMUR
YVOIR
Sequential administration of 5-azacytidine (AZA) and donor lymphocyte infusion (DLI) for patients with acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) in relapse after allogeneic stem cell transplantation.
Cliniques Universitaires UCL de Mont-Godinne
CHU Dinant-Godinne UCL Namur
BELGIUM
OOST-VLAANDEREN
GENT
A Phase 1/2, Multicenter, Dose-Escalating Study To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy Of Quizartinib Administered in Combination with Re-Induction Chemotherapy, and as a Single-Agent Maintenance Therapy, in Pediatric Relapsed/Refractory AML Subjects Aged 1 Month to <18 Years (and Young Adults Aged up to 21 Years) with FLT3-ITD mutations - BE
Kinderziekenhuis Prinses Elisabeth- UZ Gent
Pediatric Hematology-Oncology and Stem Cell Transplantation
BELGIUM
VLAAMS BRABANT
LEUVEN
HOVON 132 AML/SAKK 30/13: Randomized study with a run-in dose-selection phase to assess the added value of lenalidomide in combination with standard remission-induction chemotherapy and post-remission treatment in patients aged 18-65 years with previously untreated acute myeloid leukemia (AML) or high risk myelodysplasia (MDS) (IPSS-R risk score > 4.5) - BE
University Hospitals Leuven - Gasthuisberg
Department of Hematology
BELGIUM
VLAAMS BRABANT
LEUVEN
HOVON 102 AML / SAKK 30/09: Randomized study with a run-in feasibility phase to assess the added value of Clofarabine in combination with standard remission-induction chemotherapy in patients aged 18-65 years with previously untreated acute myeloid leukemia (AML) or myelodysplasia (MDS) (RAEB with IPSS = 1.5) (phase II-III) - BE
University Hospitals Leuven - Gasthuisberg
Department of Hematology
BELGIUM
VLAAMS BRABANT
LEUVEN
An Exploratory, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of ATIR, Donor T-lymphocytes Depleted ex Vivo of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy, Who Received a CD34-selected Hematopoietic Stem Cell Transplantation From a Haploidentical Donor (phase II)- BE (completed)
University Hospitals Leuven - Gasthuisberg
Department of Hematology
CANADA
Ontario
TORONTO
Phase 1 Study Evaluating the Tolerance and Biologic Activity of Intravenous Infusions of Tigecycline in Patients With Relapsed or Refractory AML (Completed)
Toronto General Hospital
University Health Network (UHN)
CANADA
Québec
MONTRÉAL
A Phase I/II Study of Ribavirin and Low-dose Cytarabine Arabinoside (Ara-C) in Acute Myeloid Leukemia (AML) M4 and M5 Subtypes, and AML With High eIF4E Expression (Completed)
McGill University
Department of Oncology
DENMARK
Jylland
AARHUS
NOPHO-AML 2004 Study for Children With Acute Myeloid Leukemia (Phase III)
Aarhus Universitetshospital - Skejby
Department of Pediatrics
ESTONIA
Tallinn
TALLINN
ACCEDE : 3 Open-Label Randomized Study of Amonafide L-Malate in Combination with Cytarabine Compared to Daunorubicin in Combination with Cytarabine in Patients with Secondary Acute Myeloid Leukemia (AML)
North Estonia Regional Hospital
FRANCE
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
SPARK-AML1 : A Randomised, Open-label, Multi-centre, 2-stage, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC) in Comparison With LDAC Alone in Patients Aged > 60 With Newly Diagnosed Acute Myeloid Leukaemia (AML) (Phase II) - FR
Institution: Information not provided - FR
FRANCE
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
A phase I/II, open-label, dose-escalating study to evaluate the safety, tolerability and pharmacokinetics of oral midostaurin and to evaluate the preliminary clinical and pharmacodynamic response in pediatric patients with relapsed or refractory acute leukemia - FR
Institution: Information not provided - FR
FRANCE
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
Phase IIB, multicenter, randomized, open-label trial of CPX-351 (Cytarabine:Daunorubicin) liposome injection versus intensive salvage therapy in adult patients 60 years old with AML in first relapse following an initial CR > 1 month duration
Institution: Information not provided - FR
FRANCE
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
A Phase I dose-escalation study of IPH2102, a fully human anti-KIR monoclonal antibody (CHO manufacturing), in patients with various hematologic or solid malignancies - FR
Institution: Information not provided - FR
FRANCE
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
A Phase II Study of Oral Single Agent Panobinostat in Patients with Refractory de novo or secondary Acute Myelogenous Leukemia (AML) - FR
Institution: Information not provided - FR
FRANCE
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
A Phase I, Multicenter, Open-label Study of Oral LGH447 in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome-FR
Institution: Information not provided - FR
FRANCE
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
A Phase I, Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/MK-8628 in Hematologic Malignancies - FR
Institution: Information not provided - FR
FRANCE
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
A Phase 1b Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine in Treatment-Naive Subjects With Acute Myelogenous Leukemia Who Are = 65 Years of Age and Who Are Not Eligible for Standard Induction Therapy - FR
Institution: Information not provided - FR
FRANCE
AUVERGNE-RHONE-ALPES
BRON
CLARA: A Randomized Phase II Study of Clofarabine / Intermediate-Dose Cytarabine (CLARA)Versus High-Dose Cytarabine (HDAC) as Consolidation in Younger Patients With Newly-Diagnosed Acute Myeloid Leukemia (AML)
CHU de Lyon HCL - GH Est
Centre d'Investigation Clinique
FRANCE
AUVERGNE-RHONE-ALPES
BRON
PRIMAL : A phase 1, dose escalation study of Plerixafor in combination with induction and consolidation chemotherapy in patients with relapsed acute myeloid leukemia (AML) - FR
CHU de Lyon HCL - GH Est
Centre d'Investigation Clinique
FRANCE
AUVERGNE-RHONE-ALPES
LYON
FRANCE
AUVERGNE-RHONE-ALPES
LYON
CLARA-DNX : A Phase I/II study of clofarabine in combination with cytarabine and liposomal daunorubicin in children with relapsed/refractory pediatric AML
GH Est des HCL - Institut d'Hématologie et d'Oncologie Pédiatrique (IHOPe)
Service d'immuno-hématologie pédiatrique et de transplantation de moelle osseuse
FRANCE
CENTRE-VAL DE LOIRE
TOURS
FAMYLY : Pilot Study of the Efficacy and Tolerance of the Adjunction of a Fish Oil Emulsion to Daunorubicin and Cytarabine Chemotherapy for the Treatment of Acute MYeloblastic Leukemia of Younger Patients With High-risk Cytogenetics (Phase II)
CHRU de Tours - Hôpital Bretonneau
Service d'Hématologie et Thérapie Cellulaire (HTC) adulte et pédiatrique
FRANCE
ILE-DE-FRANCE
LE CHESNAY
Treatment of acute myeloblastic leukemia in adults aged 50 to 70 years: study of two anthracyclines and continued therapy by interleukin-2 (Phase III) - Terminated -
CH de Versailles - Hôpital André Mignot
Service d'Hématologie - Oncologie
FRANCE
ILE-DE-FRANCE
LE CHESNAY
MYLOfrance 3 (ALFA0701) : A Phase III Multicentric Randomized Study of the Combination of Repeated Doses of Gemtuzumab Ozogamicin (GO) With Daunorubicin and Cytarabine Versus Daunorubicin and Cytarabine in Untreated Patients With Acute Myeloid Leukemia (AML) Aged of 50-70 Years Old
CH de Versailles - Hôpital André Mignot
Service d'Hématologie - Oncologie
FRANCE
ILE-DE-FRANCE
LE CHESNAY
PONATINIB-AML : A Phase I-II Study to Assess Safety and Efficacy of the Combination of Ponatinib With High or Intermediate-Dose Cytarabine as Consolidation Therapy for Patients With Intermediate-Risk Cytogenetic FLT3-ITD AML iIn First Complete Remission
CH de Versailles - Hôpital André Mignot
Service d'Hématologie - Oncologie
FRANCE
ILE-DE-FRANCE
LE CHESNAY
MYLOfrance 4 (ALFA1401) : Gemtuzumab Ozogamicin + Cytarabine vs Idarubicin + Cytarabine in Elderly Patients With AML (Phase II-III)
CH de Versailles - Hôpital André Mignot
Service d'Hématologie - Oncologie
FRANCE
ILE-DE-FRANCE
PARIS
TBF-Cord : Reduced Toxicity Conditioning Prior to Unrelated Cord Cell Transplantation for High Risk Myeloid Malignancies (Phase II)
CHU Paris Est - Hôpital Saint-Antoine
Service d'hématologie clinique et thérapie cellulaire
FRANCE
ILE-DE-FRANCE
PARIS
SET-HAPLO : Sequential Chemotherapy Prior to Reduced Intensity Conditioning : Interventional Study in Haploidentical Hematopoietic Stem Cells Transplantation for Patients With Refractory Acute Myeloid Leukemia
CHU Paris Est - Hôpital Saint-Antoine
Service d'hématologie clinique et thérapie cellulaire
FRANCE
ILE-DE-FRANCE
PARIS
VIDAZA-DLI : Pre-emptive Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome (Phase II)
CHU Paris Est - Hôpital Saint-Antoine
Service d'hématologie clinique et thérapie cellulaire
FRANCE
ILE-DE-FRANCE
PARIS
A Phase 1/2, Multicenter, Dose-Escalating Study To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy Of Quizartinib Administered in Combination with Re-Induction Chemotherapy, and as a Single-Agent Maintenance Therapy, in Pediatric Relapsed/Refractory AML Subjects Aged 1 Month to <18 Years (and Young Adults Aged up to 21 Years) with FLT3-ITD mutations - FR
CHU Paris Est - Hôpital d'Enfants Armand-Trousseau
Service d'Hématologie - Oncologie pédiatrique
FRANCE
ILE-DE-FRANCE
PARIS
Haploidentical NK-cell Infusion in Bad Prognosis AML Patients: Evaluation of Feasibility and Antitumoral Effect (Phase I-II) - FR
CHU Paris-GH La Pitié Salpêtrière-Charles Foix - Hôpital Pitié-Salpêtrière
Service d'Hématologie clinique
FRANCE
ILE-DE-FRANCE
PARIS
A Phase II Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Del 5q
CHU Paris-GH St-Louis Lariboisière F.Widal - Hôpital Saint-Louis
Groupe Francophone des Myélodysplasies (GFM)
FRANCE
ILE-DE-FRANCE
PARIS
A phase II study of the efficacy and safety of lenalidomide combined to azacitidine in intermediate-2 or high risk MDS AND AML with del 5q (GFM-Aza-Rev-09)
CHU Paris-GH St-Louis Lariboisière F.Widal - Hôpital Saint-Louis
Groupe Francophone des Myélodysplasies (GFM)
FRANCE
ILE-DE-FRANCE
PARIS
A phase II trial of SGI-110 in patients with ipss high and int 2 myelodysplastic syndrome, acute myeloid leukemia with 20-30% marrow blasts and chronic myelomonocytic leukemia type 2 not responding to azacitidine or decitabine after at least 6 courses or relapsing after a response
CHU Paris-GH St-Louis Lariboisière F.Widal - Hôpital Saint-Louis
Groupe Francophone des Myélodysplasies (GFM)
FRANCE
ILE-DE-FRANCE
PARIS
5-Azacitidine, Valproic Acid and ATRA in AML and High Risk MDS (Phase II) - Terminated -
CHU Paris-GH St-Louis Lariboisière F.Widal - Hôpital Saint-Louis
Service : Centre des Maladies du Sang
FRANCE
ILE-DE-FRANCE
PARIS
A Phase I study to evaluate the safety and clinical activity of WT1-A10 + AS01B Antigen-Specific Cancer Immunotherapeutic in adult patients with WT1-positive Acute Myeloid Leukemia in partial remission or complete remission with incomplete blood count recovery post-induction therapy - FR
CHU Paris-GH St-Louis Lariboisière F.Widal - Hôpital Saint-Louis
Service : Centre des Maladies du Sang
FRANCE
ILE-DE-FRANCE
PARIS
Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) (Phase III)
CHU Paris-GH St-Louis Lariboisière F.Widal - Hôpital Saint-Louis
Service d'Hématologie seniors
FRANCE
ILE-DE-FRANCE
PARIS
BERGAMO: A Phase II Study Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic Syndromes Failing Standard of Care Therapy - FR
CHU Paris-GH St-Louis Lariboisière F.Widal - Hôpital Saint-Louis
Service d'Hématologie seniors
FRANCE
ILE-DE-FRANCE
PARIS
A phase II multicentric study in adults with acute myelogenous leukaemia (AML) in first complete remission (CR1) using IV BuCy2 in a once daily Bu regimen targeting a narrow therapeutic window prior to hematopoietic stem cell transplantation
Hôpital Necker-Enfants Malades
Service d'Hématologie adulte
FRANCE
NOUVELLE AQUITAINE
PESSAC
EPAG 2015 : A phase II randomized placebo-controlled study to assess the impact on outcome of Eltrombopag administered to elderly patients with acute myeloid leukemia receiving induction chemotherapy
CHU de Bordeaux-GH Sud - Hôpital Haut-Lévêque
Service d'hématologie et thérapie cellulaire
FRANCE
OCCITANIE
MONTPELLIER
A Phase I/II Clinical Trial of PXD101 in Combination With Idarubicin in Patients With AML Not Suitable for Standard Intensive Therapy
CHU de Montpellier - Hôpital Saint-Eloi
Département d'Hématologie clinique
FRANCE
OCCITANIE
TOULOUSE
A Phase 1/2, Multicenter, Dose-Escalating Study To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy Of Quizartinib Administered in Combination with Re-Induction Chemotherapy, and as a Single-Agent Maintenance Therapy, in Pediatric Relapsed/Refractory AML Subjects Aged 1 Month to <18 Years (and Young Adults Aged up to 21 Years) with FLT3-ITD mutations - FR
CHU de Toulouse - Hôpital des Enfants
Hôpital des enfants
FRANCE
PAYS DE LA LOIRE
ANGERS
Phase II multicentric trial evaluating maintenance therapy with 6 monthly Revlimid® cycles alternated with 6 monthly Vidaza® cycles in first complete remission after induction LIA chemotherapy for elderly ( 60) fit patients with poor prognosis acute myeloid leukemia - FR
CHU d'Angers
Service des Maladies du sang
FRANCE
PAYS DE LA LOIRE
NANTES
Multicentric randomised trial comparing 1 intensive treatment with autograft and 2 intensive treatments with autograft in patients in first complete remission of AML (Phase III)
CHU de Nantes - Hôtel Dieu
Service d'hématologie clinique
FRANCE
PAYS DE LA LOIRE
NANTES
Determination of efficacy of imatinib mesylate (gleevec) in relapsed or refractory c-kit positive and bcr-abl negative acute myeloid leukemia patients (Phase II)
CHU de Nantes - Hôtel Dieu
Service d'hématologie clinique
FRANCE
PAYS DE LA LOIRE
NANTES
Cellular immune therapy evaluating injections of autologous dendritic cells pulsed with apoptotic bodies in patients with acute myeloid leukemia in 2nd CR (Phase I/II - multicentric) - Terminated -
CHU de Nantes - Hôtel Dieu
Service d'hématologie clinique
FRANCE
PAYS DE LA LOIRE
NANTES
Cloric : A Phase II Open-Label, Multicenter, Non Randomized Study Evaluating the Efficacy and the Safety of Clofarabine in Combination With IV Busulfan and Thymoglobulin (CBT) as a Reduced Intensity Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation in Adult Patients With High-Risk AML, MDS or ALL
CHU de Nantes - Hôtel Dieu
Service d'hématologie clinique
FRANCE
PAYS DE LA LOIRE
NANTES
Randomized Open Phase III Trial Testing Efficacy of Gemtuzumab Ozogamycin (MYLOTARG) Associated to Intensive Chemotherapy for Patients Aged Between 18-60 Years and Presenting an Acute Myeloid Leukemia (AML) With Intermediate Risk
CHU de Nantes - Hôtel Dieu
Service d'hématologie clinique
FRANCE
PROVENCE-ALPES-COTE D'AZUR
MARSEILLE
A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Acute Myeloid Leukemia - Terminated -
CLCC Institut Paoli Calmettes
Unité d'Evaluation Thérapeutique en Onco-Hématologie (ETHO)
FRANCE
PROVENCE-ALPES-COTE D'AZUR
MARSEILLE
A phase I-II multicenter study of the cloretazine-daunorubicin-aracytine combination for the treatment of acute myeloid leukemia (AML) with unfavorable cytogenetics
CLCC Institut Paoli Calmettes
Unité d'Evaluation Thérapeutique en Onco-Hématologie (ETHO)
FRANCE
PROVENCE-ALPES-COTE D'AZUR
MARSEILLE
A Phase II Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia - FR -
CLCC Institut Paoli Calmettes
Unité d'Evaluation Thérapeutique en Onco-Hématologie (ETHO)
FRANCE
PROVENCE-ALPES-COTE D'AZUR
MARSEILLE
Phase I dose escalation study of oral administration of S 78454 given as monotherapy in the treatment of patients with refractory or relapsed acute myeloid leukemia, acute lymphoblastic leukemia or high or intermediary-2 risk myelodysplastic syndrome
CLCC Institut Paoli Calmettes
Unité d'Evaluation Thérapeutique en Onco-Hématologie (ETHO)
FRANCE
PROVENCE-ALPES-COTE D'AZUR
MARSEILLE
Pilot Study Immunomonitoring Natural Killers Cells in Patients With Myeloid Malignancies Treated With Lenalidomide
CLCC Institut Paoli Calmettes
Département d'Oncologie Médicale
FRANCE
PROVENCE-ALPES-COTE D'AZUR
MARSEILLE
Etude Phase I/II d'immunothérapie Par protéine recWT1-A10+AS01B après Greffe allogénique de Cellules Souches (Phase I-II) - FR
CLCC Institut Paoli Calmettes
Institut Paoli-Calmettes
FRANCE
PROVENCE-ALPES-COTE D'AZUR
MARSEILLE
Prospective and Multicentre Evaluation of 3 Different Doses of IV Busulfan Associated With Fludarabine and Thymoglobuline in the Conditioning of Allogeneic Stem Cell Transplantation (SCT) From a Matched Related or Unrelated Donor in Patients With Poor Prognosis Myeloid Malignancies (Phase II) - FR
CLCC Institut Paoli Calmettes
Institut Paoli-Calmettes
GERMANY
Baden-Württemberg
FREIBURG
AML-NiloRAD: An open-label Phase I/II trial of an combination of Nilotinib (AMN 107) and RAD001 in patients with Acute Myeloid Leukemia (AML) - DE
Tumorzentrum Freiburg (CCCF)
CCCF - Comprehensive Cancer Center Freiburg
GERMANY
Baden-Württemberg
HEIDELBERG
AMLSG 07-04: Randomized phase II/III-study on All-trans Retinoic Acid in combination with induction and consolidation therapy as well as Pegfilgrastim after consolidation therapy in younger patients with newly diagnosed Acute Myeloid Leukemia (AML) - DE
Nationales Centrum für Tumorerkrankungen (NCT)
Nationales Centrum für Tumorerkrankungen (CCC) Heidelberg
GERMANY
Baden-Württemberg
HEIDELBERG
AML AZA: A randomized, multicenter phase II trial to assess the efficacy of 5-azacytidine added to standard primary therapy in elderly patients with newly diagnosed Acute Myeloid Leukemia (AML) DE
Zentrum für Innere Medizin (Krehl-Klinik)
Abteilung Innere Medizin V - Hämatologie, Onkologie und Rheumatologie
GERMANY
Baden-Württemberg
HEIDELBERG
Phase II open-label, AC220 monotherapy efficacy (ACE) study in patients with Acute Myeloid Leukemia (AML) with FLT3-ITD activating mutations - DE
Zentrum für Innere Medizin (Krehl-Klinik)
Abteilung Innere Medizin V - Hämatologie, Onkologie und Rheumatologie
GERMANY
Baden-Württemberg
TÜBINGEN
CD3/CD19 Haplo (E410/2007): Multicenter phase II study of Haploidentical Hematopoietic Cell Transplantation with CD3/CD19 depleted Grafts after a reduced intensity conditioning regimen for adult Patients with Acute Leukemia
Department für Innere Medizin - Medizinische Universitätsklinik Tübingen
Innere Medizin II - Onkologie, Hämatologie, Klinische Immunologie, Rheumatologie und Pulmologie
GERMANY
Baden-Württemberg
ULM
An open phase I/IIa trial to investigate the maximum tolerated dose, safety, efficacy and pharmacokinetics of BI 811283 in combination with Cytarabine in patients with previously untreated Acute Myeloid Leukaemia (AML) ineligible for intensive treatment (BI 811283 1247.3) - DE
Universitätsklinikum Ulm am Oberen Eselsberg
Klinik für Innere Medizin III
GERMANY
Baden-Württemberg
ULM
CLASSIC I: A Phase III Randomized, Double-blind, Controlled Study Comparing Clofarabine and Cytarabine Versus Cytarabine Alone in Adult Patients 55 Years and Older With Acute Myelogenous Leukemia (AML) Who Have Relapsed or Are Refractory After Receiving up to Two Prior Induction Regimens
Universitätsklinikum Ulm am Oberen Eselsberg
Klinik für Innere Medizin III
GERMANY
Baden-Württemberg
ULM
AMLSG 11-08: Open-label, multicenter phase Ib/IIa study for the evaluation of Dasatinib following induction and consolidation therapy as well as in maintenance therapy in patients with newly diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)
Universitätsklinikum Ulm am Oberen Eselsberg
Klinik für Innere Medizin III
GERMANY
Baden-Württemberg
ULM
AMLSG 19-13: Dose Finding Run-in Phase I Followed by a Phase III, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of Crenolanib in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia and Activating FLT3 Mutations - DE
Universitätsklinikum Ulm am Oberen Eselsberg
Klinik für Innere Medizin III
GERMANY
Bayern
MÜNCHEN
A Phase II Study Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic Syndromes Failing Standard of Care Therapy -DE-
Klinikum rechts der Isar der Technischen Universität München
Klinik und Poliklinik für Innere Medizin III
GERMANY
Bayern
MÜNCHEN
AML-CG 2008: A Randomized, risk and age adapted comparison of the dose-dense regimen S-HAM (sequential high dose cytosine arabinoside and mitoxantrone) versus standard double induction for initial Chemotherapy of adult patients with Acute Myeloid Leukemia (Phase III)
LMU Klinikum der Universität München - Campus Großhadern
Medizinische Klinik und Poliklinik III
GERMANY
Bayern
MÜNCHEN
Midostaurin in MRD (Minimal Residual Disease) Positive Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation
Ludwig-Maximilians-Universität München
Klinikum der Universität München
GERMANY
Berlin
ADDRESS: NOT PROVIDED - DE
Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) (Phase III) - DE
Institution: Information not provided - DE
GERMANY
Berlin
ADDRESS: NOT PROVIDED - DE
WT1 Vaccination: Phase II Study of WT1 126-134 Peptide Vaccination in Combination With Adjuvants GM-CSF and KLH in AML - DE
Institution: Information not provided - DE
GERMANY
Berlin
ADDRESS: NOT PROVIDED - DE
CLBH589H2101 - A phase I/b, open-label, multicenter, dose-escalation study of oral panobinostat (LBH589) administered with 5-azacitidine (Vidaza®) in adult patients with Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) - DE
Institution: Information not provided - DE
GERMANY
Berlin
ADDRESS: NOT PROVIDED - DE
AZA-AML-004: A randomized, multicenter, open-label, Phase 2 study with a safety run-in part to evaluate safety, pharmacodynamics and efficacy of azacitidine compared to no anticancer treatment in children and young adults with acute myeloid leukemia in molecular relapse after first complete remission -DE-
Institution: Information not provided - DE
GERMANY
Berlin
ADDRESS: NOT PROVIDED - DE
A Phase 1/2 Study of Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Subjects With Acute Myelogenous Leukemia Who Are Greater Than or Equal to 60 Years of Age and Who Are Not Eligible for Standard Anthracycline-Based Induction Therapy -DE-
Institution: Information not provided - DE
GERMANY
Berlin
ADDRESS: NOT PROVIDED - DE
A Phase 1b Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine in Treatment-Naive Subjects With Acute Myelogenous Leukemia Who Are = 65 Years of Age and Who Are Not Eligible for Standard Induction Therapy -DE-
Institution: Information not provided - DE
GERMANY
Berlin
ADDRESS: NOT PROVIDED - DE
An Exploratory, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of a Two-dose Regimen of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted ex Vivo of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy, Who Received a CD34-selected Hematopoietic Stem Cell Transplantation From a Haploidentical Donor -DE-
Institution: Information not provided - DE
GERMANY
Hamburg
HAMBURG
RICMAC: A randomized phase III study: dose-reduced versus standard conditioning followed by allogenic stem cell transplantation in patients with myelodysplastic syndrome or secondary acute myeloid leukemia - DE
UKE - Universitätsklinikum Hamburg-Eppendorf
Interdisziplinäre Klinik und Poliklinik für Stammzelltransplantation
GERMANY
Hamburg
HAMBURG
AMLSG 10-07: Phase I/II clinical study of SU11248 (Sutent) combined with standard chemotherapy with Cytosine Arabinoside and Daunorubicin in patients with FLT3 mutated Acute Myeloid Leukemia (AML) over 60 years of age - DE
UKE - Universitätsklinikum Hamburg-Eppendorf
II. Medizinische Klinik und Poliklinik - Onkologie, Hämatologie
GERMANY
Hessen
FRANKFURT AM MAIN
A Prospective Phase I/II Study to Investigate the Feasibility, Safety and Efficacy of IL-15 Activated Cytokine Induced Killer (CIK) Cells in Relapsing Patients With Acute Leukemia or Myelodysplastic Syndromes After Allogeneic SCT - DE
Klinikum der Johann Wolfgang Goethe-Universität Frankfurt
Schwerpunkt Stammzelltransplantation und Immunologie
GERMANY
Hessen
FRANKFURT AM MAIN
KKS/INNERE_A/AML2006 Sorafenib (Elderly): A double-blind, placebo-controlled, randomized, multicenter phase II trial to assess the efficacy of Sorafenib added to standard primary therapy in Patients up to 61years with newly diagnosed Acute Myeloid Leukemia (AML) - DE
Klinikum der Johann Wolfgang Goethe-Universität Frankfurt
Medizinische Klinik II - Hämatologie und Onkologie
GERMANY
Hessen
FRANKFURT AM MAIN
PANOBEST: Phase I/II study with oral panobinostat maintenance therapy following allogeneic stem cell transplantation in patients with high risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)
Klinikum der Johann Wolfgang Goethe-Universität Frankfurt
Medizinische Klinik II - Hämatologie und Onkologie
GERMANY
Hessen
MARBURG
SORMAIN: A double-blind, placebo-controlled, randomised, multicentre phase II trial to assess the efficacy and safety of Sorafenib-maintenance therapy in Flt3-ITD positive Acute Myeloid Leukemia in complete haematological remission after allogenic stem cell transplantation
Universitätsklinikum Gießen und Marburg GmbH, Standort Marburg
Klinik für Innere Medizin - Schwerpunkt Hämatologie, Onkologie und Immunologie
GERMANY
Niedersachsen
HANNOVER
AML-BFM 2004 : Multicenter therapy-optimization trial for the treatment of Acute Myeloid Leukemias in children and adolescents - DE
KPOH Geschäftsführung Hannover
Kompetenznetz Pädiatrische Onkologie und Hämatologie
GERMANY
Niedersachsen
HANNOVER
AML SCT-BFM 2007 : Phase III multicenter therapy study: Allogenic Stem Cell Transplantation for children, adolescents and young adults with relapsed or refractory Acute myeloid Leukemia (AML) - DE
Medizinische Hochschule Hannover
Klinik für Pädiatrische Hämatologie und Onkologie
GERMANY
Nordrhein-Westfalen
DÜSSELDORF
Phase-II trial to assess the efficacy and toxicity of 5-Azacitidine in addition to standard donor lymphocyte for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome relapsing after allogeneic stem cell transplantation
Universitätsklinikum Düsseldorf
Klinik für Hämatologie, Onkologie und Klinische Immunologie
GERMANY
Nordrhein-Westfalen
DÜSSELDORF
AZALENA: Phase-II Trial to Assess the Efficacy and Safety of Lenalidomide in Addition to 5-Azacitidine and Donor Lymphocyte Infusions (DLI) for the Treatment of Patients With MDS, CMML or AML Who Relapse After Allogeneic Stem Cell Transplantation - DE
Universitätsklinikum Düsseldorf
Klinik für Hämatologie, Onkologie und Klinische Immunologie
GERMANY
Nordrhein-Westfalen
ESSEN
AML-BFM 2004 : Multicenter therapy-optimization trial for the treatment of Acute Myeloid Leukemias in children and adolescents - DE
Universitätsklinikum Essen
Klinik für Kinderheilkunde III - Abteilung für pädiatrische Hämatologie und Onkologie
GERMANY
Nordrhein-Westfalen
LEVERKUSEN
CP4055-205: A Phase II Study of Elacytarabine (CP-4055) plus Idarubicin as second course remission-induction therapy in patients with Acute Myeloid Leukaemia (AML) - DE
Klinikum Leverkusen
Medizinische Klinik 3 - Onkologie, Hämatologie, Palliativmedizin, Spezielle Schmerztherapie
GERMANY
Sachsen
DRESDEN
Gentuzumab ozogamicin before allogeneic stem cell transplantation in patients with relapsed CD33+ Acute Myeloid Leukemia (Phase I-II) - DE
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I - Fachbereich Hämatologie und Blutstammzelltransplantation
GERMANY
Sachsen
DRESDEN
TUD-LENAMA-022: Lenalidomide maintenance therapy in patients with Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukaemia (AML) - Phase II study - DE
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I - Fachbereich Hämatologie und Blutstammzelltransplantation
GERMANY
Sachsen
DRESDEN
TUD-RELAZA-008: Treatment of the haematological relapse in patients with AML and MDS following allogenic Stem Cell Transplantation with 5-Azacitidine (Vidaza®) (Phase III) - DE
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I - Fachbereich Hämatologie und Blutstammzelltransplantation
GERMANY
Sachsen
LEIPZIG
An open-label, multicenter study of monotherapy or in combination with azacitidine for patients with post-myeloproliferative disorders (Phase I/II) - DE
Abteilung für Hämatologie und Internistische Onkologie
GERMANY
Sachsen-Anhalt
MAGDEBURG
CLDE225X2203: A Phase II multicenter, open label, randomized study to assess safety and efficacy of two different schedules of oral LDE225 in adult patients with relapsed / refractory or untreated elderly patients with Acute Leukemia - DE
Universitätsklinikum Magdeburg A.ö.R
Universitätsklinik für Hämatologie und Onkologie
GERMANY
Thüringen
JENA
Phase II study of Cladribine, high-dose Cytarabine and Idarubicin in patients with relapsed acute myeloid leukemia - DE
Universitätsklinikum Jena
Klinik für Innere Medizin II - Abteilung Hämatologie und Internistische Onkologie
GERMANY
Thüringen
JENA
Midostaurin in MRD (Minimal Residual Disease) Positive Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation
Universitätsklinikum Jena
Klinik für Innere Medizin II - Abteilung Hämatologie und Internistische Onkologie
IRELAND
County Dublin
DUBLIN
A Phase 1b Study to Evaluate the Safety and Efficacy of MEDI4736 as Monotherapy and in Combination With Tremelimumab or AZD9150 in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma - IE
St James's Hospital
Department of Medical Oncology
IRELAND
County Galway
GALWAY
A Phase I/II, Open-label Multicenter Trial to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia - IE
University Hospital Galway
Department of Haematology
IRELAND
County Galway
GALWAY
A Phase 1b Study to Evaluate the Safety and Efficacy of MEDI4736 as Monotherapy and in Combination With Tremelimumab or AZD9150 in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma - IE
University Hospital Galway
ITALY
FRIULI VENEZIA GIULIA
UDINE
Induction, Consolidation and Intensification Therapy for Patients Younger Than 66 Years With Previously Untreated CD33 Positive Acute Myeloid Leukemia (AML)
Azienda Ospedaliero-Universitaria "Santa Maria della Misericordia" di Udine
Clinica Ematologica
ITALY
LAZIO
ROMA
Risk-adapted, MRD-directed Therapy for Young Adults With Newly Diagnosed Acute Myeloid Leukemia
Azienda Ospedaliera Universitaria Policlinico di Tor Vergata
U.O.C. Ematologia
ITALY
LAZIO
ROMA
Study protocol for acute myeloid leukemia in children and adolescent
IRCCS Ospedale Pediatrico Bambino Gesù - SEDE GIANICOLO
U.O. di Onco-Ematologia
ITALY
LAZIO
ROMA
Clofarabine in combination with standard remission induction regimen (AraC and idarubicin) in patients 20-60 years old with previously untreated intermediate and bad risk acute myelogenous leukemia (AML)
Sapienza Università di Roma - Dipartimento di Neurologia e Psichiatria
Dipartimento di Biotecnologie Cellulari ed Ematologia
ITALY
LOMBARDIA
MILANO
Multicenter Phase II Study of Haploidentical Hematopoietic Cell Transplantation With CD3/CD19 Depleted Grafts After a Reduced Intensity Conditioning Regimen for Adult Patients With Acute Leukemia
IRCCS Ospedale San Raffaele
Dipartimento di Ematologia
ITALY
MARCHE
PESARO
Phase II multicenter study of low dose Cytarabine + Tosedostat for previously untreated older patients with acute myeloid leukemia (AML)
A.O. Ospedali Riuniti Marche Nord - Presidio San Salvatore Centro
Ematologia e Centro Trapianti
NETHERLANDS
Gelderland
NIJMEGEN
The Value of High Dose Versus Standard Dose ARA-C During Induction and of IL-2 After Intensive Consolidation/Autologous Stem Cell Transplantation in Patients (Age 15-60 Years) With Acute Myelogenous Leukemia. A Randomized Phase III Trial
Radboudumc - Radboud universitair medisch centrum
Afdeling Hematologie
NETHERLANDS
Gelderland
NIJMEGEN
Gemtuzumab Ozogamicin (GO) Combined With Standard Intensive Chemotherapy Versus Standard Intensive Chemotherapy Alone For Induction/Consolidation In Patients 61-75 Years Old With Previously Untreated AML: A Randomized Phase III Trial
Radboudumc - Radboud universitair medisch centrum
Afdeling Hematologie
NETHERLANDS
Gelderland
NIJMEGEN
Gemtuzumab Ozogamicin (GO) Monotherapy Versus Standard Supportive Care for Previously Untreated AML in Elderly Patients Who Are Not Eligible for Intensive Chemotherapy: A Randomized Phase II/III Trial
Radboudumc - Radboud universitair medisch centrum
Afdeling Hematologie
NETHERLANDS
Gelderland
NIJMEGEN
A randomized study of tipifarnib versus best supportive care (including hydroxyurea) in the treatment of newly diagnosed acute myeloid leukemia (AML) in subjects 70 years or older
Radboudumc - Radboud universitair medisch centrum
Afdeling Hematologie
NETHERLANDS
Gelderland
NIJMEGEN
Clofarabine in Combination With a Standard Remission Induction Regimen (AraC and Idarubicin) in Patients 18-60 Years Old With Previously Untreated Intermediate and Bad Risk Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS) : a Phase I-II Study of the EORTC-LG and GIMEMA (AML-14A Trial)
Radboudumc - Radboud universitair medisch centrum
Afdeling Hematologie
NETHERLANDS
Gelderland
NIJMEGEN
A Phase I/II, Open Label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1152 in Patients With Acute Myeloid Leukaemia
Radboudumc - Radboud universitair medisch centrum
Afdeling Hematologie
NETHERLANDS
Gelderland
NIJMEGEN
High dose Ara-C in combination with Gemtuzumab Ozogamicin (ARGO) as salvage treatment for primary resistant AML patients 18 - 60 yrs old
Radboudumc - Radboud universitair medisch centrum
Afdeling Tumor Immunologie
NETHERLANDS
Zuid-Holland
LEIDEN
Clofarabine in combination with a standard remission induction regimen (AraC and idarubicin) in patients 18-60 years old with previously untreated intermediate and bad risk acute myelogenous leukemia (AML) or high risk myelodysplasia (MDS): a phase I-II study of the EORTC-LG and GIMEMA (AML-14A trial)
LUMC - Leids Universitair Medisch Centrum
Afdeling Hematologie
NETHERLANDS
Zuid-Holland
LEIDEN
Prophylactic infusion of CD4 positive donor lymphocytes early after T-cell depleted allogeneic stem cell transplantation in patients with an unrelated donor (phase II)
LUMC - Leids Universitair Medisch Centrum
Afdeling Hematologie
NETHERLANDS
Zuid-Holland
ROTTERDAM
Reduced intensity chemotherapy given with and without Imatinib Mesylate in patients >/= 60 years considered unfit for standard chemotherapy with previously untreated Acute Myeloid Leukemia (AML) and refractory anemia with excess of Blasts (RAEB, RAEB-T); A randomized phase II study.
Erasmus MC - Erasmus Medisch Centrum
Afdeling Hematologie
NORWAY
Vestlandet
BERGEN
A Phase II Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia - NO -
Haukeland University Hospital
POLAND
Lodz
LODZ
Evaluation of the Efficacy of Induction-consolidation Treatment Using a Double Induction in Patients With AML <60 Years Old, Depending on the Percentage of Blasts in the 14 Day, Residual Disease and Leukemic Hematopoietic Cells
Wojewodzki Szpital Specjalistyczny im. M. Kopernika w Lodzi
Oddzial Hematologii
SPAIN
Castilla - León
SALAMANCA
PANOBIDARA: A Phase I/II Multicenter, National, Open-Label Study of Panobinostat in Combination With Idarubicin and Cytarabine in Patients Aged 65 Years or Older With Newly Diagnosed Acute Myeloblastic Leukaemia (AML) - ES (completed)
Hospital Clínico Universitario de Salamanca
Servicio de Hematología
SPAIN
Castilla - León
SALAMANCA
A Phase I/II National, Open-Label, Multicenter Study of Bortezomib (Velcade) in Combination With FLAG-IDA (VFLAG- IDA) in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) (completed)
Hospital Clínico Universitario de Salamanca
Servicio de Hematología
SPAIN
Cataluña
BADALONA
APL-R2007: Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO) (Phase IV) (completed)
ICO Badalona - Hospital Germans Trias i Pujol
Servicio de Hematología Clínica
SPAIN
Cataluña
BARCELONA
APL-R2007: Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO) (Phase IV) (completed)
Hospital Clínic de Barcelona
Servicio de Hematología
SPAIN
Cataluña
BARCELONA
FLAT: Fludarabine, Cytarabine and Topotecan in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia (Phase IV) (terminated)
Hospital Universitari Vall d'Hebron
Servicio de Hematología y hemoterapia
SPAIN
Cataluña
BARCELONA
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy (Phase II/III) - ES (Completed)
Hospital de la Santa Creu i Sant Pau
Servicio de Hematología
SPAIN
Comunidad Valenciana
VALENCIA
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy (Phase II/III) - ES (Completed)
Hospital Clínico Universitario de Valencia
Servicio de Oncología
SPAIN
Comunidad Valenciana
VALENCIA
PANOBIDARA: A Phase I/II Multicenter, National, Open-Label Study of Panobinostat in Combination With Idarubicin and Cytarabine in Patients Aged 65 Years or Older With Newly Diagnosed Acute Myeloblastic Leukaemia (AML) - ES (completed)
Hospital Universitario y Politécnico La Fe
Servicio de Hematología y Hemoterapia
SPAIN
Comunidad Valenciana
VALENCIA
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy (Phase II/III) - ES (Completed)
Hospital Universitario y Politécnico La Fe
Servicio de Hematología y Hemoterapia
SPAIN
Comunidad Valenciana
VALENCIA
Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005): Remission Induction With ATRA + Idarubicin. Risk-adapted Consolidation With ATRA and Anthracycline-based Chemotherapy (Idarubicin/Mitoxantrone) With Addition of Ara-C for High-risk Patients... (Phase IV) (completed)
Hospital Universitario y Politécnico La Fe
Servicio de Hematología y Hemoterapia
SPAIN
Comunidad Valenciana
VALENCIA
APL-R2007: Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO) (Phase IV) (completed)
Hospital Universitario y Politécnico La Fe
Servicio de Hematología y Hemoterapia
SPAIN
Comunidad Valenciana
VALENCIA
PETHEMA LAM07: Prospective, Multicenter, Uncontrolled Cohort Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML) (Phase IV) (completed)
Hospital Universitario y Politécnico La Fe
Servicio de Hematología y Hemoterapia
SPAIN
Comunidad Valenciana
VALENCIA
LENA-LMA-5: Pilot Study Phase II, Multicenter, Non-randomized, to Assess the Efficacy and Safety of Lenalidomide in Induction and Post-Induction in Patients with Novo Acute Myeloid Leukemia (AML) with Cytogenetic Abnormality Monosomy 5 (terminated)
Hospital Universitario y Politécnico La Fe
Servicio de Hematología y Hemoterapia
SPAIN
Comunidad Valenciana
VALENCIA
Multicentric Phase II Trial, Prospective, Open, Single Group, to Discuss Induction Therapy With a Combination of Clofarabine and Low-dose Cytarabine Followed by Consolidation Therapy With Clofarabine and Low-dose Cytarabine for the Treatment of AML Patients Age Greater Than or Equal to 60 Years (completed)
Hospital Universitario y Politécnico La Fe
Servicio de Hematología y Hemoterapia
SPAIN
Comunidad Valenciana
VALENCIA
A multicenter, double-blind, randomized, placebo-controlled, phase III study of idasanutlin, an MDM2 antagonist, with cytarabine versus cytarabine plus placebo in patients with relapsed or refractory acute myeloid leukemia (AML) - ES
Hospital Universitario y Politécnico La Fe
Servicio de Hematología y Hemoterapia
SPAIN
Comunidad Valenciana
VALENCIA
FLUGAZA: A phase III, multicentre, randomized, open label clinical trial comparing azacytidine (Vidaza®) versus fludarabine plus cytarabine in elderly patients with newly diagnosed acute myeloid leukemia - ES
Hospital Universitario y Politécnico La Fe
Servicio de Hematología y Hemoterapia
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
Randomized study with a run-in feasibility phase to assess the added value of Clofarabine in combination with standard remission-induction chemotherapy in patients aged 18-65 years with previously untreated acute myeloid leukemia (AML) or myelodysplasia (MDS) (RAEB with IPSS >= 1.5) (Phase II-III) - ES (terminated)
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
Phase 1-2 Safety and Efficacy Study of DACOGEN in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia - ES (completed)
Institution: Information not provided - ES
SPAIN
Madrid
LEGANÉS
Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005): Remission Induction With ATRA + Idarubicin. Risk-adapted Consolidation With ATRA and Anthracycline-based Chemotherapy (Idarubicin/Mitoxantrone) With Addition of Ara-C for High-risk Patients... (Phase IV) (completed)
Hospital Universitario Severo Ochoa
Servicio de Hematología
SPAIN
Madrid
MADRID
PANOBIDARA: A Phase I/II Multicenter, National, Open-Label Study of Panobinostat in Combination With Idarubicin and Cytarabine in Patients Aged 65 Years or Older With Newly Diagnosed Acute Myeloblastic Leukaemia (AML) - ES (completed)
Hospital Clínico San Carlos
Servicio de Hematología y Hemoterapia
SPAIN
Madrid
MADRID
A Phase I/II National, Open-Label, Multicenter Study of Bortezomib (Velcade) in Combination With FLAG-IDA (VFLAG- IDA) in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) (completed)
Hospital Clínico San Carlos
Servicio de Hematología y Hemoterapia
SPAIN
Madrid
MADRID
Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005): Remission Induction With ATRA + Idarubicin. Risk-adapted Consolidation With ATRA and Anthracycline-based Chemotherapy (Idarubicin/Mitoxantrone) With Addition of Ara-C for High-risk Patients... (Phase IV) (completed)
Hospital Clínico San Carlos
Servicio de Hematología y Hemoterapia
SPAIN
Madrid
MADRID
APL-R2007: Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO) (Phase IV) (completed)
Hospital Clínico San Carlos
Servicio de Hematología y Hemoterapia
SPAIN
Madrid
MADRID
Prospective Study of the Value of the Cytogenetic and of the Monitoring of the Minimal Residual Disease [Acute Myeloblastic Leukemia] (Phase IV) (terminated)
Hospital Clínico San Carlos
Servicio de Hematología y Hemoterapia
SPAIN
Madrid
MADRID
Clinical trial phase I/II, single-center, historical control, to evaluate the effectiveness of donor IL-15-stimulated NK cells post transplant infusion, in acute leukemia patients with poor prognosis and haploidentical unmanipulated transplant - ES
Hospital General Universitario Gregorio Marañón
Servicio de Hematología y Hemoterapia
SPAIN
Madrid
MADRID
A Phase 1/2, Multicenter, Dose-Escalating Study To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy Of Quizartinib Administered in Combination with Re-Induction Chemotherapy, and as a Single-Agent Maintenance Therapy, in Pediatric Relapsed/Refractory AML Subjects Aged 1 Month to <18 Years [...] with FLT3-ITD mutations - ES
Hospital Infantil Universitario Niño Jesús
Servicio de Oncohematología
SPAIN
Madrid
MADRID
PANOBIDARA: A Phase I/II Multicenter, National, Open-Label Study of Panobinostat in Combination With Idarubicin and Cytarabine in Patients Aged 65 Years or Older With Newly Diagnosed Acute Myeloblastic Leukaemia (AML) - ES (completed)
Hospital Universitario 12 de Octubre
Servicio de Hematología y Hemoterapia
SPAIN
Madrid
MADRID
A Phase I/II National, Open-Label, Multicenter Study of Bortezomib (Velcade) in Combination With FLAG-IDA (VFLAG- IDA) in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) (completed)
Hospital Universitario 12 de Octubre
Servicio de Hematología y Hemoterapia
SPAIN
Madrid
MADRID
APL-R2007: Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO) (Phase IV) (completed)
Hospital Universitario 12 de Octubre
Servicio de Hematología y Hemoterapia
SPAIN
Madrid
MADRID
Natural Killer cell infusion as consolidation therapy in children and adolescents with acute myelogenous leukemia (Phase II) - ES
Hospital Universitario La Paz
Servicio de Hemato-Oncología Pediátrica
SPAIN
Madrid
MADRID
A Phase 1/2, Multicenter, Dose-Escalating Study To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy Of Quizartinib Administered in Combination with Re-Induction Chemotherapy, and as a Single-Agent Maintenance Therapy, in Pediatric Relapsed/Refractory AML Subjects Aged 1 Month to <18 Years [...] with FLT3-ITD mutations - ES
Hospital Universitario La Paz
Servicio de Hemato-Oncología Pediátrica
SPAIN
Madrid
MADRID
PANOBIDARA: A Phase I/II Multicenter, National, Open-Label Study of Panobinostat in Combination With Idarubicin and Cytarabine in Patients Aged 65 Years or Older With Newly Diagnosed Acute Myeloblastic Leukaemia (AML) - ES (completed)
Hospital Universitario Ramón y Cajal
Servicio de Hematología y Hemoterapia
SPAIN
Madrid
MADRID
A Phase I/II National, Open-Label, Multicenter Study of Bortezomib (Velcade) in Combination With FLAG-IDA (VFLAG- IDA) in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) (completed)
Hospital Universitario Ramón y Cajal
Servicio de Hematología y Hemoterapia
SPAIN
Madrid
MADRID
PETHEMA-LAM99: Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years (Phase IV) (terminated)
Hospital Universitario Ramón y Cajal
Servicio de Hematología y Hemoterapia
SPAIN
Madrid
MADRID
VALOR: A Phase 3, Randomized, Controlled, Double-Blind, Multinational Clinical Study of the Efficacy and Safety of Vosaroxin and Cytarabine Versus Placebo and Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia (Completed)
M.D. Anderson Cancer Center Madrid
Servicio de Hematología
SPAIN
Madrid
MADRID
A Phase 1B/2 Study To Evaluate The Safety And Efficacy of PF-04449913, An Oral Hedgehog Inhibitor, In Combination With Intensive Chemotherapy, Low Dose ARA-C Or Decitabine In Patients With Acute Myeloid Leukemia Or High-Risk Myelodysplastic Syndrome - ES (Completed)
M.D. Anderson Cancer Center Madrid
Servicio de Hematología
SPAIN
Madrid
MADRID
Maintenance therapy with 5-Azacitidine in patients with acute myeloid leukemia who are not eligible for intensive treatment and with partial or complete response after induction chemotherapy (Phase II) - ES (terminated)
M.D. Anderson Cancer Center Madrid
Servicio de Hematología
SPAIN
Navarra
PAMPLONA
TK008: Randomized Phase III Trial of Haploidentical HCT With or Without an Add Back Strategy of HSV-Tk Donor Lymphocytes in Patients With High Risk Acute Leukemia - ES
Complejo Hospitalario de Navarra - Hospital Virgen del Camino
Servicio de Hematología y Hemoterapia
UNITED KINGDOM
Devon
EXETER
WT1 Immunity via DNA fusion Gene Vaccination in Haematological Malignancies by intramuscular injection followed by intramuscular electroporation - WIN: Anti-WT1 DNA fusion gene vaccine in haematological malignancies
Royal Devon and Exeter Hospital - Wonford site
Department of Haematology
UNITED KINGDOM
Essex
HARLOW
ASPIRE: A three-part, phase II study of Eltrombopag in thrombocytopenic subjects with Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: open-label, part 2: randomized, double-blind, part 3: extension) - DE
GlaxoSmithKline Research & Development Ltd.
GlaxoSmithKline Research & Development Limited
UNITED KINGDOM
Greater London
LONDON
CaspaCide TCR α β haplo HSCT: Follow-up of Phase 1/2 Study of CaspaCIDe T Cells (BPX-501) From an HLA-partially Matched Family Donor After Negative Selection of TCR α β+T Cells in Pediatric Patients Affected by Hematological Disorders-GB
GOSH NHS Foundatin Trust
Great Ormond Street Hospital
UNITED KINGDOM
Greater London
LONDON
UK Haplo v1.0: A UK multicentre phase II study of haploidentical stem cell transplantation in patients with haematological malignancies
Guy's Hospital
Department of Haematology
UNITED KINGDOM
Greater London
LONDON
An Exploratory, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of ATIR, Donor T-lymphocytes Depleted ex Vivo of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy, Who Received a CD34-selected Hematopoietic Stem Cell Transplantation From a Haploidentical Donor - GB
Hammersmith Hospital
Hammersmith Hospital Haemophilia Centre
UNITED KINGDOM
Greater London
LONDON
WT1 Immunity via DNA fusion Gene Vaccination in Haematological Malignancies by intramuscular injection followed by intramuscular electroporation - WIN: Anti-WT1 DNA fusion gene vaccine in haematological malignancies
Imperial College NHS Trust
UNITED KINGDOM
Greater London
LONDON
A Phase I Study of the Human Pharmacokinetics and Cardiac Safety of Elacytarabine - GB
St Bartholomew's Hospital, Barts and The London NHS Trust
Department of Medical Oncology
UNITED KINGDOM
Greater London
UXBRIDGE
UNITED KINGDOM
Greater Manchester
ADDRESS: NOT PROVIDED - UK
A Phase 3, Multicenter, Randomized, Open-Label, Study of Azacitidine (Vidaza®) Versus Conventional Care Regimens for the Treatment of Older Subjects With Newly Diagnosed Acute Myeloid Leukemia - UK
Institution: Information not provided - UK
UNITED KINGDOM
Greater Manchester
ADDRESS: NOT PROVIDED - UK
UNITED KINGDOM
Greater Manchester
ADDRESS: NOT PROVIDED - UK
An Exploratory, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of a Two-dose Regimen of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted ex Vivo of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy, Who Received a CD34-selected Hematopoietic Stem Cell Transplantation From a Haploidentical Donor - GB
Institution: Information not provided - UK
UNITED KINGDOM
Hampshire
SOUTHAMPTON
A Pilot Study of Clofarabine Pre-Conditioning Prior to Full or Reduced Intensity Allogeneic Transplantation in the Treatment of High Risk Acute Myeloid Leukaemia and Myelodysplasia - Clofarabine pre-conditioning with allogeneic transplant for AML
Southampton General Hospital
University Hospitals Southampton NHS Foundation Trust
UNITED KINGDOM
Hampshire
SOUTHAMPTON
WT1 Immunity via DNA fusion Gene Vaccination in Haematological Malignancies by intramuscular injection followed by intramuscular electroporation - WIN: Anti-WT1 DNA fusion gene vaccine in haematological malignancies
University of Southampton
School of Medicine (Medical Oncology)
UNITED KINGDOM
Nottinghamshire
NOTTINGHAM
A Phase 2, Randomized, Open-Label Study of the Safety and Efficacy of Two Doses of Quizartinib (AC220; ASP2689) in Subjects with FLT3-ITD Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) - UK
LAM Action Nottingham, Voluntary Action Centre
Nottingham Haematology Group
UNITED KINGDOM
South Glamorgan
CARDIFF
UNITED KINGDOM
South Glamorgan
CARDIFF
AML 16: A Programme of Treatment Development for Older Patients With Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome (PhaseII/III)
Cardiff University School of Medicine
Department of Medical Genetics, Haematology & Pathology
UNITED KINGDOM
South Glamorgan
CARDIFF
AML 17: Randomised, controlled, open label, multi-arm trial looking at treatment for acute promyelocytic leukaemia (Phase III)
Cardiff University School of Medicine
Department of Medical Genetics, Haematology & Pathology
UNITED KINGDOM
South Glamorgan
CARDIFF
AML 15: Medical research council working parties on leukaemia in adults and children. Acute myeloid leukaemia trial 15 (Phase III)
Cardiff University School of Medicine
Department of Medical Genetics, Haematology & Pathology
UNITED KINGDOM
South Glamorgan
CARDIFF
AML-HR: Protocol for patients with high risk (resistant, refractory, relapsed or adverse cytogenetic) AML (Phase III)
Cardiff University School of Medicine
Department of Medical Genetics, Haematology & Pathology
UNITED KINGDOM
South Glamorgan
CARDIFF
A national cancer research institute acute myeloid leukaemia working group pilot trial under the auspices of the cardiff experimental cancer medicine centre to establish the feasibility of combining the tyrosine kinase inhibitor, ponatinib with chemotherapy in patients with acute myeloid leukaemia with a flt3 mutation. - AML19 Pilot
Cardiff University School of Medicine
Department of Medical Genetics, Haematology & Pathology
UNITED KINGDOM
South Glamorgan
CARDIFF
VALOR: A Phase 3, Randomized, Controlled, Double Blind, Multinational Clinical Study of the Efficacy and Safety of Vosaroxin and Cytarabine Versus Placebo and Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia - UK
University Hospital of Wales
Department of Haematology
UNITED KINGDOM
West Midlands
BIRMINGHAM
CLOUD: CLOfarabine Used with DaunoXome: Phase I dose escalation study of clofarabine and liposomal daunorubicin in childhood and adolescent AML
Birmingham Children's Hospital NHS Foundation Trust
UNITED KINGDOM
West Midlands
BIRMINGHAM
DACOGENAML2004 - Phase 1-2 Safety and Efficacy Study of DACOGEN in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia - UK
Birmingham Children's Hospital NHS Foundation Trust
UNITED KINGDOM
West Midlands
BIRMINGHAM
FIGARO - A Randomised Trial of the FLAMSA-BU Conditioning Regimen in Patients with Acute Myeloid Leukaemia and Myelodysplasia Undergoing Allogeneic Stem Cell Transplantation
Queen Elizabeth Hospital
CRUK Clinical Trials Unit
UNITED KINGDOM
West Midlands
BIRMINGHAM
RAvVA: Phase II Randomised Trial of 5-Azacitidine versus 5-Azacitidine in combination with Vorinostat in patients with Relapsed Acute Myeloid Leukaemia ineligible for Intensive Chemotherapy
Queen Elizabeth Hospital
CRUK Clinical Trials Unit
UNITED KINGDOM
West Midlands
BIRMINGHAM
NCRN627 - A phase 1/2, dose and schedule finding study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of oral azacitidine (cc-486) in subjects with acute myeloid leukemia or myelodysplastic syndromes after allogeneic hematopoietic stem cell transplantation - UK
Queen Elizabeth Hospital
CRUK Clinical Trials Unit
UNITED KINGDOM
West Midlands
BIRMINGHAM
UNITED KINGDOM
West Midlands
BIRMINGHAM
UNITED KINGDOM
West Midlands
BIRMINGHAM
Single Arm Phase II trial assessing the safety, compliance with and activity of Bezafibrate and medroxyProgesterone acetate (BaP) as non-toxic therapy against myeloid and lymphoid cancers - BaP
University of Birmingham
School of Cancer Sciences
UNITED KINGDOM
West Midlands
BIRMINGHAM
PARC: Phase I/II Study Evaluating the Safety and Activity of Pegylated Recombinant Human Arginase (BCT-100) in Relapsed/Refractory Cancers of Children and Young Adults -GB
University of Birmingham
University of Birmingham HQ
UNITED KINGDOM
West Yorkshire
LEEDS
NCRN105: A phase II study of oral single agent Panobinostat in patients with refectory Acute Myelogenous Leukaemia
National Cancer Research Coordinating Centre
UNITED STATES
Alabama
BIRMINGHAM
A Randomized, Double-blind Phase 1b/2 Study Of Pf-04449913 (Glasdegib) In Combination With Azacitidine In Patients With Previously Untreated Intermediate-2 Or High-risk Myelodysplastic Syndrome, Acute Myeloid Leukemia With 20-30% Blasts And Multi-lineage Dysplasia, Or Chronic Myelomonocytic Leukemia - US
University of Alabama at Birmingham
UNITED STATES
Alabama
BIRMINGHAM
Multi-center Single Arm Phase II Study of Myeloablative Allogeneic Stem Cell Transplantation for Non-remission Acute Myeloblastic Leukemia (AML) Using Clofarabine and Busulfan x 4 (CloBu4) Regimen (Phase II) (Completed)
University of Alabama at Birmingham
UNITED STATES
California
DUARTE
Multi-center Single Arm Phase II Study of Myeloablative Allogeneic Stem Cell Transplantation for Non-remission Acute Myeloblastic Leukemia (AML) Using Clofarabine and Busulfan x 4 (CloBu4) Regimen (Phase II) (Completed)
City of Hope
City of Hope National Medical Center
UNITED STATES
Michigan
ANN ARBOR
Multi-center Single Arm Phase II Study of Myeloablative Allogeneic Stem Cell Transplantation for Non-remission Acute Myeloblastic Leukemia (AML) Using Clofarabine and Busulfan x 4 (CloBu4) Regimen (Phase II) (Completed)
University of Michigan UH B1 H410/0028
University of Michigan
UNITED STATES
New Jersey
EAST HANOVER
A Phase 1b Study to Evaluate the Safety and Efficacy of MEDI4736 as Monotherapy and in Combination With Tremelimumab or AZD9150 in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma - GB
Novartis Pharmaceutical Corporation
UNITED STATES
New Jersey
EAST HANOVER
A Phase 1b Study to Evaluate the Safety and Efficacy of MEDI4736 as Monotherapy and in Combination With Tremelimumab or AZD9150 in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma - IE
Novartis Pharmaceutical Corporation
UNITED STATES
New York
MANHASSET
CLTR0308-205 : Phase IIB, multicenter, randomized, open-label trial of CPX-351 (Cytarabine:Daunorubicin) liposome injection versus intensive salvage therapy in adult patients < or = 60 years old with AML in first relapse following an initial CR > 1 month duration - FR
North Shore University Hospital
UNITED STATES
Washington
ADDRESS: NOT PROVIDED - US
A Phase 1/2, Multicenter, Dose-Escalating Study To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy Of Quizartinib Administered in Combination with Re-Induction Chemotherapy, and as a Single-Agent Maintenance Therapy, in Pediatric Relapsed/Refractory AML Subjects Aged 1 Month to <18 Years (and Young Adults Aged up to 21 Years) with FLT3-ITD mutations - FR
Institution: Information not provided - US
UNITED STATES
Washington
ADDRESS: NOT PROVIDED - US
A Phase 1b Study to Evaluate the Safety and Efficacy of MEDI4736 as Monotherapy and in Combination With Tremelimumab or AZD9150 in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma - GB
Institution: Information not provided - US
UNITED KINGDOM
Greater London
LONDON
An open-label, uncontrolled, multicenter, multinational study on the efficacy and safety of administration of donor lymphocytes depleted of alloreactive T-cells (ATIR), through the use of TH9402 and light treatment in an ex vivo process, in patients receiving a CD34-selected peripheral blood stem cell graft from a related, haploidentical donor (Phase II/III)
Faculty of Medicine - Imperial College of London
Centre for Haematology
FRANCE
ILE-DE-FRANCE
VILLEJUIF
(APL-A-005-02) Phase I - II clinical and pharmacokinetic study of Aplidin (APL) as a 3-hour intravenous infusion every 2 weeks, in children with refractory or relapsed malignant tumours and leukaemia -Terminated -
CLCC Institut Gustave Roussy
Département de Cancérologie de l'enfant et de l'adolescent
BELGIUM
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
STEP: Sorafenib Long Term Extension Program - BE
Cliniques Universitaires UCL Saint-Luc
Pneumologie_Oncologie thoracique
Multinational clinical trial(s)
GERMANY
Berlin
ADDRESS: NOT PROVIDED - DE
AMoRE2017: International multicenter, open-label, phase 2 study to treat molecular relapse of pediatric acute myeloid leukemia with azacitidine
Institution: Information not provided - DE
GERMANY
Berlin
ADDRESS: NOT PROVIDED - DE
SAMBA-trial: Single Agent JNJ-56022473 in MDS and AML Patients Failing Hypomethylating Agent Based Therapy
Institution: Information not provided - DE
SWITZERLAND
Suisse Romande
ADDRESS: NOT PROVIDED - CH
A Phase IB/II Multi-Arm Study With Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Institution: Information not provided - CH
SWITZERLAND
Suisse Romande
ADDRESS: NOT PROVIDED - CH
A Phase Ib/II Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission
Institution: Information not provided - CH
UNITED KINGDOM
Greater Manchester
ADDRESS: NOT PROVIDED - UK
SEAMLESS: A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia
Institution: Information not provided - UK
UNITED STATES
Massachusetts
BOSTON
A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PKC412) (IND #101261) or Placebo in Newly Diagnosed Patients < 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia (AML)
Dana-Farber Cancer Institute Boston
Dana-Farber Cancer Institute
UNITED STATES
Washington
ADDRESS: NOT PROVIDED - US
A Phase 3, Multicenter, Open-label, Randomized Study of SGI-110 versus Treatment Choice (TC) in Adults with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Considered Candidates for Intensive Remission Induction Chemotherapy
Institution: Information not provided - US
UNITED STATES
Washington
ADDRESS: NOT PROVIDED - US
A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation
Institution: Information not provided - US
UNITED STATES
Washington
ADDRESS: NOT PROVIDED - US
A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy
Institution: Information not provided - US
UNITED STATES
Washington
ADDRESS: NOT PROVIDED - US
Efficacy Study of Inecalcitol in Combination with Decitabine in Acute Myeloid Leukemia Patients Unfit for Standard Chemotherapy
Institution: Information not provided - US
UNITED STATES
Washington
ADDRESS: NOT PROVIDED - US
UNITED STATES
Washington
ADDRESS: NOT PROVIDED - US
A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia
Institution: Information not provided - US
NORWAY
Østlandet
OSLO
SWEDEN
Stockholms läns landsting
ADDRESS: NOT PROVIDED - SE
SPARK-AML1: A Randomised, Open-label, Multi-centre, 2-stage, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC) in Comparison With LDAC Alone in Patients Aged > 60 With Newly Diagnosed Acute Myeloid Leukaemia (AML) (Phase II) (coordination)
Institution: Information not provided - SE
UNITED KINGDOM
Greater London
LONDON
The ACCEDE Study: Phase III Open-Label Randomized Study of Amonafide L-Malate in Combination With Cytarabine Compared to Daunorubicin in Combination With Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML) (coordination)
Antisoma Research Ltd.
Antisoma Research Ltd
UNITED STATES
California
SAN DIEGO
Phase 2 Open-Label, AC220 Monotherapy Efficacy (ACE) Study in Patients With Acute Myeloid Leukemia (AML) With FLT3-ITD Activating Mutations (coordination)
Ambit Biosciences Corporation
UNITED STATES
New Jersey
EDISON
UNITED STATES
New Jersey
RARITAN
Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) (Phase III) (coordination)
Johnson & Johnson
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
UNITED STATES
Texas
HOUSTON
CaspaCide TCR α β haplo HSCT: Follow-up of Phase 1/2 Study of CaspaCIDe T Cells (BPX-501) From an HLA-partially Matched Family Donor After Negative Selection of TCR α β+T Cells in Pediatric Patients Affected by Hematological Disorders
Bellicum Pharmaceuticals, Inc.
UNITED STATES
Washington
ADDRESS: NOT PROVIDED - US
Phase 1b, Multi-arm, Open-label Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Institution: Information not provided - US
SPAIN
Madrid
COLMENAR VIEJO